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Abstract: Cardiac fibrosis, the excessive accumulation of extracellular matrix (ECM), remains an
unresolved problem in most forms of heart disease. In order to be successful in preventing, attenuating
or reversing cardiac fibrosis, it is essential to understand the processes leading to ECM production
and accumulation. Cardiac fibroblasts are the main producers of cardiac ECM, and harbor great
phenotypic plasticity. They are activated by the disease-associated changes in mechanical properties
of the heart, including stretch and increased tissue stiffness. Despite much remaining unknown,
an interesting body of evidence exists on how mechanical forces are translated into transcriptional
responses important for determination of fibroblast phenotype and production of ECM constituents.
Such mechanotransduction can occur at multiple cellular locations including the plasma membrane,
cytoskeleton and nucleus. Moreover, the ECM functions as a reservoir of pro-fibrotic signaling
molecules that can be released upon mechanical stress. We here review the current status of
knowledge of mechanotransduction signaling pathways in cardiac fibroblasts that culminate in
pro-fibrotic gene expression.
Keywords: fibrosis; cardiac fibroblast; myofibroblast; mechanotransduction; stiffness; extracellular
matrix; integrins; syndecan; cytoskeleton; linker of the nucleoskeleton and cytoskeleton
1. Cardiac Fibrosis and Heart Disease
Cardiac fibrosis, the excessive accumulation of extracellular matrix (ECM), occurs in nearly
all types of heart disease including myocardial infarction, aortic stenosis, dilated cardiomyopathy,
diabetic cardiomyopathy and hypertrophic cardiomyopathy [1–6]. It is characterized by dysregulated
production, post-translational modification, enzymatic processing and turnover of collagens
(mainly type I and III in the heart) and other ECM components such as proteoglycans [2,7–9].
Cardiac fibrosis comes in several forms, i.e., perivascular, interstitial and focal, and this ECM
remodeling increases the risk for arrhythmias and may reduce pumping function as in heart failure
with reduced ejection fraction (HFrEF). Cardiac fibrosis is also a main driver of heart failure with
preserved ejection fraction (HFpEF) as it increases myocardial stiffness, thereby compromising the
distensibility of the ventricles and impairing the filling capacity of the heart [10].
There is to date no effective treatment for cardiac fibrosis. This could, in part, be due to the
poor understanding of the function of the cell type responsible for ECM production, the cardiac
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fibroblast [11–15]. Currently, the cardiac ECM and fibroblast pathophysiology are under intense
investigation [16]. The ECM is accepted as a dynamic and active player in health and disease and
a central role for cardiac fibroblasts in development of fibrosis has been established [9]. Hopefully,
this expanding effort and accumulation of knowledge will lead to the discovery of novel targets and
anti-fibrotic therapies.
In order to be successful in preventing, attenuating or reversing cardiac fibrosis, it is essential
to understand the processes leading to ECM production and accumulation [2]. Altered mechanical
properties of the heart occurs early in many types of cardiac disease [17]. Thus, in addition to
increased neurohormonal activity [18,19] and sterile inflammation [20,21] that are well-known to
increase ECM production, mechanical factors are crucial for the development of fibrosis. How these
mechanical cues are translated into cardiac fibroblast responses is not completely understood. We here
review the current state of knowledge on pro-fibrotic mechanotransduction signaling pathways in
cardiac fibroblasts.
2. Mechanical Forces of the Heart
Cells in the heart are continuously subjected to different types of mechanical forces, and changes
in these mechanical forces during cardiac disease induce responses in cardiac fibroblasts. Stress and
strain in the heart wall are three-dimensional and non-uniform. In addition to normal tensile (pulling)
and compressive (pushing) components, parallel and transverse to the planes of the wall, there is
significant shearing (friction) during filling and ejection, as evidenced by the torsional deformations
seen during the cardiac cycle. An overview of the mechanical terms used to describe the various
mechanical forces of the heart is presented in Box 1.
Since stresses represent the three-dimensional forces of interaction within the tissue, they cannot
be measured directly, mostly because any device or implant intended to measure tissue stresses
inevitably affects them. Therefore, wall stress distributions are estimated with the aid of computational
models [22] that solve Newton’s force balance equations for the myocardium. The models make use of
knowledge of the three-dimensional mechanical properties of the muscle at rest and during contraction,
and the known external loads acting on the heart walls, namely the chamber and pericardial pressures.
On the other hand, strains represent three-dimensional regional shape (i.e., length) changes in
the tissue such as systolic fiber shortening and wall thickening. Their regional distributions can be
measured non-invasively in humans and animal models using techniques such as speckle tracking
echocardiography [23] or tagged magnetic resonance imaging (MRI) [24], both of which rely on imaging
the motion of material points in the walls. By comparing measured three-dimensional strains with
models, their computations of wall stress can be reliably validated. However, it remains challenging to
relate macroscopic wall stresses and strains with cell scale mechanics. For example, how stresses are
distributed between myofilaments and the ECM can still be challenging to discriminate definitively.
To understand the direct effect of force on cardiac fibroblast phenotype, in vitro systems have
been developed. These include measuring passive and active tensile forces of intact myocardial strips,
and applying strain to cells by static or cyclic stretching of cardiac cell cultures. These methods have
been extensively reviewed elsewhere [25]. More recently, the effect of matrix stiffness on cardiac
fibroblast phenotype has received great attention as fibroblasts harbor great plasticity and alter
their phenotype in response to tissue and ECM stiffness [25–29]. Stiffness is measured in Pascal
(Pa), describing the material’s Young’s elastic modulus. By the use of atomic force microscopy,
stiffness has been estimated to be 10 kPa for the healthy myocardium and 20–100 kPa for the
fibrotic myocardium [30,31], whereas standard culturing conditions have stiffness in the GPa (109 Pa)
range. Hence, standard in vitro cultures of cardiac fibroblasts are, in most cases, representative of
myofibroblasts. To maintain a quiescent cardiac fibroblast phenotype in vitro, cells must be cultured
on soft hydrogels where the stiffness can be tuned to better mimic the in vivo mechanical environment.
These include polyacrylamide gels [32–34] and hyaluronic acid gels that can be stiffened or softened
during cell culturing [35–37]. However, few studies have to date combined soft hydrogels with the
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application of stretch [25,27,38,39]. Thus, much is yet to be learned about the stretch-induced responses
of quiescent cardiac fibroblasts and how each of the mechanical cues observed in the intact heart are
translated into biological alterations in fibroblast function and fibrosis.
Box 1. Mechanical forces of the heart.
Strain refers to the deformation of a material. Strain is positive if the material fibers are stretched and negative if
they are compressed.
Stress is force per unit area.
Tensile forces are pulling forces that act to lengthen a material in the direction of the applied force.
Tensile stress is the tensile force per unit area. Tensile stress applied to a material gives rise to tensile strain,
which measures the lengthening (i.e., stretch) of a material. Tensile stress developed by a cell (due to myofilament
or cytoskeletal contraction) will tend to cause compressive strain or shortening along the axis of tension
development. During ventricular filling, acute diastolic tensile stress and strain is applied to the myocardium,
while chronic left ventricular pressure overload will increase the tensile stress in the myocardium during systole.
Stiffness is the extent to which a material resists deformation in response to an applied force, and is the inverse
of compliance. Extracellular matrix (ECM) stiffness is mainly determined by fibrillar collagens (collagen type
I and III in the heart) and the degree of collagen cross-linking [40–42]. Cell stiffness is largely determined by
prestress [43].
Prestress is the stress remaining in the cell or tissue when external forces on the tissue are removed.
Cellular prestress is often attributed to tension in stress fibers of the cytoskeleton balanced by compression in
microtubules and/or cytoplasmic pressure (positive pressure is a negative, compressive stress). In tissue or cells
adhered to ECM, these pulling forces are resisted by external tethers to the ECM. Prestress is modulated by cell
stiffness [43] and essential for cell differentiation [44].
Cell traction force is the tension exerted on the ECM and other cells via adhesion receptors (integrins and
cadherins) as a result of cell shortening of the contracting cytoskeleton. It can be computed from measurements
of the strains induced by cell contraction.
Compressive force is a pushing force; External forces that act to shorten the material in the direction of the
applied force are compressive.
Shear tractions are tangential forces per unit area such as those due to friction or forces applied by a cell adhered
to a matrix surface. The torsional rotation of the ventricle during filling and ejection creates shearing stresses
caused by the helical arrangement of myofibers in the wall. Transverse shearing stresses and strains also exist
between myocardial laminar “sheets” during systole [45]. In vascular biology, shear stress frequently refers to
the forces of fluid flow on the surface of cells e.g., due to blood flow. These shear stresses tend to be orders of
magnitude lower than shear stresses due to cell interactions with solid matrix but are still biologically significant.
3. Cardiac Fibroblasts and Mechanotransduction
Cardiac fibroblasts are essential in health and disease. In the healthy heart they are rather
quiescent, with low ECM producing activity maintaining a baseline turnover of ECM proteins.
Biochemical and mechanical cues activate cardiac fibroblasts leading to increased production of
ECM [25,46] (Figure 1). This is beneficial in the initial phase after a myocardial infarction or induction
of pressure overload of the heart, as it enables adjustment of ECM production to meet the requirements
of the changing extracellular environment [47]. As such, upregulation of ECM genes and remodeling
of the ECM ensures structural stability to withstand increases in mechanical load and repair the
myocardium following injury; e.g., fibrosis is necessary to prevent myocardial rupture following an
infarction. However, persistently high ECM-producing activity is associated with myocardial stiffening
and impaired function [11,48].
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Figure  1.  Cardiac  fibroblasts  are  located  in  between  cardiomyocytes  where  they  ensure  the 
appropriate amount and composition of extracellular matrix (ECM) in the healthy heart. Mechanical 
stress  induces  fibrosis  during  cardiac  remodeling,  e.g.,  hypertrophic  remodeling.  Fibrosis 
compromises cardiac function, and results from activation of cardiac fibroblasts and transition into a 
myofibroblast phenotype characterized by excessive production of ECM. 
The activated  cardiac  fibroblast exhibits multiple overlapping phenotypes  [47,49] with  some 
common characteristics  that distinguish  them  from quiescent  fibroblasts. These  include  increased 
proliferation,  excessive production  of ECM,  large  and  strong  focal  adhesions,  and  expression  of 
smooth muscle  α‐actin  (SMA),  the  contractile actin  filament which  is part of  the normal  smooth 
muscle cell’s contractile cytoskeleton.  Incorporation of SMA  into stress  fibers enables a  slow and 
endured  contraction  (also  called  contracture),  resulting  in  rearrangement  and  remodeling  of  the 
ECM. Due to this smooth muscle‐like phenotype, fully activated cardiac fibroblasts are referred to as 
myofibroblasts  [46].  Recently,  it  was  demonstrated  that  cardiac  fibroblasts  can  also  adopt 
alternative  cell  fates  following myocardial  injury  [50]  including an osteoblast‐like  fate associated 
with the calcification process accompanying fibrosis [51], underlining the vast plasticity of cardiac 
fibroblasts. 
Many  cell  types may  adopt  a myofibroblast phenotype  in vitro. Thus,  the  cellular origin of 
pro‐fibrotic  cardiac  myofibroblasts  in  vivo  has  been  debated.  The  traditional  view  is  that 
myofibroblasts in the heart derive from resident cardiac fibroblasts and this is supported by lineage 
tracing studies using the collagen type I alpha 1 chain (collagen1a1) gene promoter controlling the 
green  fluorescent protein  (GFP)  reporter  [52]. This view has been  challenged by  the  finding  that 
endothelial  cells  [53],  bone‐marrow‐derived  circulating  progenitor  cells  [54,55],  and  pericytes 
surrounding blood vessels [56] can also adopt a myofibroblast phenotype and hence contribute to 
the  cardiac  myofibroblast  population.  However,  recent  compelling  evidence  demonstrate  that 
transcription  factor  21  (Tcf21)‐expressing  tissue‐resident  fibroblasts  indeed  give  rise  to  cardiac 
myofibroblasts and deletion of Tcf21‐expressing fibroblasts blunt the development of fibrosis [57]. 
Thus, it seems that the majority of cardiac myofibroblasts are indeed derived from resident cardiac 
fibroblasts [58].   
No  specific marker  protein  exclusively  expressed  in  the myofibroblast  has  been  identified, 
possibly  due  to  the  range  of  fibroblast‐to‐myofibroblast  phenotypes.  Myofibroblasts  are  most 
commonly  defined  by  high  expression  of  collagen  I,  and  de  novo  expression  of  SMA  and  the 
Figure 1. Cardiac fibroblasts are located in between cardiomyocytes where they ensure the appropriate
amount and composition of extracellular matrix (ECM) in the healthy heart. Mechanical stress induces
fibrosis during cardiac remodeling, e.g., hypertrophic remodeling. Fibrosis compromises cardiac
function, and results from activation of cardiac fibroblasts and transition into a myofibroblast phenotype
characterized by excessive production of ECM.
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process a comp nyi g fibrosis [51], underlining the vast plasticity of cardiac fibroblasts.
Many cell types may adopt a myofibroblast phenotype in vitro. Thus, the cellular origin of
pro-fibrotic ardiac myofibroblasts in viv has been debated. The traditi nal view is that myofibroblasts
in the heart de ive fro resident cardiac fibr blasts and this is supported by lineage tracing studies
using the collagen type I alpha 1 chain (collagen1a1) gene p moter controlling the gre n fluorescent
protein (GFP) reporter [52]. This view has been challenged by the findi g that endothelial cells [53],
bone-marrow-derived circulating progenitor cells [54,55], and pericytes surroun ing blood vessels [56]
can also adopt a myofibroblast phenotyp and hence contribute to the cardiac myofibrobl st population.
However, recent compel ing evidence demonstrate that transcription factor 21 (Tcf21)-expressing
issue- esident fibroblasts indeed give rise t cardiac myofibr blasts and deletion of Tcf21-expr ssing
fibroblas s blunt the developm nt of fibrosi [57]. Thus, it seems that the majority of
fi re inde d derived from reside t cardiac fibroblas s [58].
No specific marker protein exclusively exp essed in the myofibroblast has been identified,
possibly due to the range of fibroblast-to-myofibroblast phenotypes. Myofibroblasts are most
comm nly defined by high xpression of collag n I, a d de novo expre sion of SMA and the
extradomain A (EDA) splic variant f fibronectin [59]. Also, platelet-derived growth factor rec ptor β
(PDGFRβ) [60] an the matric llular protein periosti are de novo expressed in myofibroblasts [57,61].
Mechanical cues are major drivers of cardiac fibroblast activation [49] and act directly on
cardiac fibroblasts, or by inducing paracrine signals from mechanically stressed cardiomyocytes [50].
An example of the latter was recently demonstrated by our group showing an increase in
cardiac fibroblast proliferation when cultured in the same media as stretched cardiomyocytes [39].
Persistent elevated stretch of cardiac fibroblasts stimulates sustained production of ECM [39,62]
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causing myocardial stiffening. Interestingly, stretch-induced transcription of certain ECM genes is
dependent on matrix stiffness; i.e., cardiac fibroblasts cultured on 3 kPa substrates display different
stretch responses than cardiac fibroblasts on 8 kPa substrates [39]. Although the stiffer myocardium
will be more resistant to stretch, the mechanical force that arises with the increased stiffness will itself
support continued activity of myofibroblasts [39]. As such, the cellular component of focal fibrotic
regions of the heart is almost exclusively myofibroblasts [63]. A better understanding of how activated
cardiac fibroblasts respond to ECM stiffness and stretch will be important for therapeutic targeting of
fibrosis [64].
Cells interpret mechanical forces by mechanotransduction, the conversion of mechanical stimuli
into chemical activity [65]. Changes in the cell’s mechanical environment cause activation of
intracellular signaling pathways that lead to changes in gene expression, cell phenotype and
function. Mechanotransduction can occur at multiple cellular locations including the plasma
membrane, cytoskeleton and nucleus (Figure 2). Moreover, the ECM can be “activated” by stretch
and stiffening [9,66,67]. Due to the great importance of strain and stiffening for pathological
ECM remodeling, cell responses to these forces have been the focus of numerous studies and will
reviewed here.
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Figure 2. Mechanical forces are translated into biochemical activity by mechanotransduction, which 
occurs at different cellular sites and by “activation” of the ECM. In cardiac fibroblasts, mechanical 
stress leads to pro‐fibrotic gene expression. 
4. Mechanical Activation of Extracellular Matrix: A Vigilant Pro‐Fibrotic Reservoir 
Both stretch and stiffness of the ECM will determine how prone the ECM is to “activation”; i.e., 
the liberation of ECM‐derived molecules that stimulate pro‐fibrotic cell responses [9,64]. Although 
not traditionally considered mechanotransduction, compelling evidence describes ECM “activation” 
Figure 2. Mechanical forces are translated into biochemical activity by mechanotransduction,
which occurs at different cellular sites and by “activation” of the ECM. In cardiac fibroblasts, mechanical
stress leads to pro-fibrotic gene expression.
4. Mechanical Activation of Extracellular Matrix: A Vigilant Pro-Fibrotic Reservoir
Both stretch and stiffness of the ECM will determine how prone the ECM is to “activation”;
i.e., the liberation of ECM-derived molecules that stimulate pro-fibrotic cell responses [9,64].
Although not traditionally considered mechanotransduction, compelling evidence describes ECM
“activation” by myofibroblasts as a central part of fibrosis development [60,67–71]. ECM stiffness is
in constant balance with the cell’s intrinsic stiffness, or pre-stress [43]. However, myofibroblasts gain
contractile properties allowing them to “pull” on the ECM. This is termed cell traction forces (Box 1)
and has recently been shown to activate ECM-stored signaling molecules in a specific manner [60,68].
There is also evidence suggesting that an excessively stretched ECM will release or expose signaling
molecules that are normally concealed by the intact ECM. This may represent a mechanism to alert
resident cells of increased mechanical burden [21,72].
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4.1. Transforming Growth Factor β Activation; A Potent Signal Activated in ECM during Increased Stress
Transforming growth factor β (TGFβ) is the most well-known driver of myofibroblast
differentiation [73], inducing pro-fibrotic gene expression through the canonical signaling pathway
with activation of Smad2/3, and through non-canonical signaling pathways including activation of
Rho-MRTF-A (myocardin-related transcription factor A) [74]. TGFβ is secreted to the extracellular
environment in an inactive protein complex consisting of TGFβ and latency-associated propeptide
(LAP) which binds to latent TGFβ binding protein 1 (LTBP-1) in the ECM [75–77]. The LAP contains an
Arg-Gly-Asp (RGD) sequence which is a common ligand for several integrins including αv. As such,
all αv integrins are known to bind to RGD in LAP [60,69,70,75,78], and liberate TGFβ from its binding
complex in response to cell traction forces (Figure 3) [60,79,80]. This enables storage of TGFβ in the
ECM wherefrom it can be rapidly activated upon cellular contraction by myofibroblasts.
Interestingly, stretch can induce release of active TGFβ from the ECM even in the absence of
cells, suggesting that increased ECM stretch will mechanically open the latent complex and activate
TGFβ. The amount of stretch necessary to activate TGFβ varies among tissues and depends on the
degree of ECM organization, with highly organized ECM having higher bioavailability of TGFβ [81].
Such cell-independent effects of stretch on TGFβ activation have been demonstrated in tendon,
a connective tissue characterized by highly organized collagen fibrils with high stretch burden [82].
Accompanying the variations in stiffness among tissues, it seems logic that the mechanical thresholds
for TGFβ activation and thus pathological myofibroblast differentiation vary according to the basic
stretch level.
Critical regulators of ECM organization are the cross-linking enzymes lysyl oxidase (LOX) and
transglutaminase 2 (TG2). LOX and LOX-like (LOXL) enzymes are upregulated in the heart in response
to mechanical stress and are associated with fibrosis, diastolic dysfunction and heart failure [40,83,84].
In addition to increasing collagen organization and thus TGFβ bioavailability, LOXL2 was recently
found to stimulate cardiac fibroblasts to produce TGFβ, further enhancing TGFβ signaling [84].
Inhibition or genetic disruption of LOXL2 reduced cardiac fibrosis in response to left ventricular
pressure overload and improved overall cardiac function [84].
Direct activation of TG2 by cellular traction forces has been demonstrated for vascular smooth
muscle cells [85]. The extracellular domain of the transmembrane proteoglycan syndecan-4 has
been shown to promote collagen cross-linking through regulation of cell surface TG2 trafficking
and activity [86–88], and collagen cross-linking by LOX in in vitro [89], suggesting that cells may
regulate ECM structure and thus TGFβ bioavailability through inside-out signaling. Although only
demonstrated for TGFβ, mechanical activation of ECM-stored growth factors and cytokines may
represent a general mechanism for initiation of pro-fibrotic signaling [90–92].
J. Clin. Med. 2017, 6, 53 7 of 31
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Figure 3. Mechanotransduction signaling pathways in the cardiac fibroblast. Hyaluronic
acid (HA), small leucine-rich proteoglycans (SLRPs), latent TGFβ binding protein 1 (LTBP1),
transforming growth factor β (TGFβ), T Fβ receptor (TGFβR), integrins (itg), syndecan (syn),
transient receptor potential (TRP) channel, toll-like receptor (TLR), focal adhesion kinase
(FAK), Yes-associated protein (YAP), transcriptio al c activator with PDZ-binding motif (TAZ),
myocardin-related tr nscripti n factor (MRTF), nuclear factor of activated T-cells (NFAT), uclear
factor kappa-light-chain-enhancer of activated B cells (NFκB), danger-associated molecular patterns
(DAMPs), calcineurin (CaN), smooth muscle α-actin (SMA), linker of nucleoskeleton and cyt skelet n
LINC), transcription factors (TF).
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4.2. DAMPs Are Stress-Induced Initiators of Inflammation and Fibrosis
The ECM may itself activate cardiac fibroblasts in response to mechanical stress by activating
toll-like receptors (TLRs; Figure 3). TLRs are central for the innate immune system’s response
to pathogen-associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) derived
from the bacterial cell wall. Endogenous molecules that activate these same pathways are called
danger-associated molecular patterns (DAMPs) and are associated with sterile inflammation [21].
DAMPs include intracellular cell components such as mitochondrial DNA [93,94], heat-shock
proteins [95–97], high mobility group box 1 (HMGB1) [98,99] and IL1α [100,101] that are released into
the extracellular space during cellular stress, as well as ECM-derived molecules released during tissue
damage. The latter group includes tenascin C [102], fibronectin EDA [72], and ECM-localized small
leucine-rich proteoglycans (SLRPs) biglycan and decorin [103].
Downstream signaling of TLRs involves activation of the transcription factor nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB). Lumican, also a member of the SLRP
family, induces pro-fibrotic signaling through activation of NFκB and is associated with increased
cardiac fibrosis and development of heart failure in mice subjected to left ventricular pressure
overload [104,105]. Moreover, the shed extracellular domain of the transmembrane proteoglycan
syndecan-4 activates NFκB, and affects transcription of collagens and SMA in cultured cardiac
fibroblasts [106]. Smaller fragments of the large extracellular carbohydrate chain hyaluronic acid (HA)
have also been found to activate TLRs [107,108]. Although there is no direct proof that mechanical
forces alone can induce the release of ECM-derived DAMPs, it is plausible that high mechanical load
will cause some degree of ECM damage with the consequence of DAMP release. SLRPs, syndecans,
glypicans and hyaluronic synthase (HAS) 1 and 2 are upregulated in the pressure overloaded
heart [104,105,109–112] and could represent such DAMPs in the mechanically stressed heart.
Conceptually, the role of ECM as a reservoir for pro-fibrotic signaling molecules is attractive.
The existence of signaling factors that are ready to be released from the ECM by mechanical force
would constitute a rapid and efficient mechanism for alarming cardiac fibroblasts of tissue injury or
stress. Presumably, the amount of force needed to release DAMPs by mechanical disruption of the
ECM is somewhat higher than the force needed for the specific activation of TGFβ. Such a difference
in activation threshold would enable responses fine-tuned to the degree of a mechanical burden.
5. Cell Surface Mechanotransduction: A Strained Relationship between the ECM and
Cell Interior
Mechanotransduction at the cell surface culminates at focal adhesions, specialized plasma
membrane protein complexes comprised of adhesion receptors, signaling molecules and cytoskeletal
proteins [113]. Mechanotransduction is mediated through transmembrane adhesion receptors that
have the unique ability to sense the extracellular mechanical environment and translate it into cellular
responses. They are attached to the ECM as well as the cytoskeleton thereby forming a physical link
from the exterior to the interior of the cell. Of these transmembrane adhesion proteins, integrins are
the best understood when it comes to mechanotransduction [114] but also other proteins such as
transmembrane proteoglycans [109] can transmit mechanical signals across the membrane (Figure 3).
Since mechanotransduction can occur in both directions, cell surface signaling through adhesion
receptors is often referred to as inside-out and outside-in signaling [115,116]. Mechanotransduction
between neighboring cells can occur through cell-cell attachment sites called adherans junctions.
This has recently been reviewed for cardiac fibroblasts elsewhere [114], thus we here focus on ECM-cell
mediated mechanotransduction.
5.1. Integrins Are Main Constituents of Focal Adhesions Integrating Extracellular and Intracellular Signals
Integrins are adhesion receptors that exist as heterodimers consisting of one α and one β subunit.
Upon binding to extracellular ligands, including fibronectin and collagen, integrins cluster to form focal
adhesions. In addition to being essential for focal adhesion assembly, integrins are central mediators
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of mechanotransduction. Integrins interact with 156 known partners collectively referred to as the
“integrin adhesome” [117]. Considering this large number of interaction partners, it is no surprise that
integrins cross-talk with other membrane receptors and down-stream signaling pathways including
G-protein coupled receptors [118] and tyrosine kinase receptors [119,120], affecting adrenergic and
growth factor signaling. Comprehensive reviews of integrin cross-talk in the context of fibrosis have
been published previously [119,121,122]. Here we discuss the direct down-stream signaling pathways
of various integrins that are activated by mechanical cues and associated with fibrosis in the heart.
Cardiac fibroblasts express several of the 24 known integrins, many of which are upregulated
during development of cardiac fibrosis [114]. Stretch-induced activation of pro-fibrotic signaling
pathways depends on which integrin subunits are enganged [123]. Many cardiac β1 integrins
can induce cardiac myofibroblast differentiation in response to mechanical forces [114,124],
including collagen receptors α1β1 and α3β1, and fibronectin receptors α5β1 and α8β1, and have been
associated with differences observed between soft (healthy) and hard (fibrotic) hearts [68,125–129].
Of the β2 integrins, α1β2 is the main collagen I-binding integrin of the healthy heart and, in contrast
to the disease-associated β1 integrins, α1β2 is protective against fibrosis as it regulates collagen I
turnover by inducing production of matrix metalloproteinase 1 [130–133]. Thus, blocking this integrin
causes accumulation of collagen and development of fibrosis. β3 integrins bind to RGD sequences
of collagen, fibronectin and vitronectin and are necessary for pressure overload-induced myocardial
fibrosis [134,135] and have been shown to play a role in mechanical induction of myofibroblast
differentiation [136].
The collagen-binding integrin α11β1 is particularly enriched at sites with well-organized
interstitial collagen networks [137] and has been associated with fibrosis in several organs including
the heart [138–142]. α11 is involved in myofibroblast differentiation [139,141,143], and binds strongly
to glycated collagen thereby inducing pro-fibrotic signaling [143]. In vivo, glycated cardiac collagen
is associated with a stiffer matrix [42,144], suggesting that α11 may be important for sensing and
regulating myocardial stiffness. Indeed, studies in cancer-associated fibroblasts show a close link
between presence of α11 and extent of collagen cross-linking [145], an important determinant of ECM
stiffness. Furthermore, α11 is associated with left ventricular remodeling in patients with heart failure
and genetically modified mice lackingα11 have attenuated diabetes-related cardiac fibrosis [146]. It will
be important to pinpoint the mechanisms whereby α11 induces fibrosis in response to mechanical cues.
Since integrins have no intrinsic enzymatic activity, down-stream signaling relies on intracellular
interaction with enzymes and adaptor proteins through their cytoplasmic domain [147]. The adaptor
protein talin forms a link from integrins to the cytoskeleton and mediates recruitment of signaling
molecules to focal adhesions in response to mechanical stimuli [148]. Deletion of talin prevents
fibrosis in the pressure-overloaded heart by preventing activation of the signaling molecules
mitogen-activated protein kinase (MAPK) p38, extracellular signal-regulated protein kinases 1 and 2
(ERK1/2), protein kinase B (PKB/Akt) and glycogen synthase kinase 3β [149]. Interestingly, it was
recently shown that talin is necessary for sensing substrate stiffness [150]. Above a rigidity threshold
of 5 kPa, talin structure unfolded thereby recruiting vinculin, promoting focal adhesion formation and
inducing cell traction forces and nuclear translocation of the mechanosensitive transcription regulator
Yes-associated protein (YAP). These results place talin in the center of mechanotransduction in response
to substrate stiffness [150].
Integrins directly and rapidly activate nonreceptor protein tyrosine kinases such as focal adhesion
kinase (FAK), Src and Fyn in response to tension and stiffness [39,151,152]. FAK induces a cascade
of signaling events involving ERK1/2 and MAPKs [115] which are known to induce myofibroblast
differentiation and ECM production [153–155]. FAK, Src and Fyn facilitate the activation of Rho
GTPases through activating guanine nucleotide exchange factors (GEFs) and GTPases-activating
proteins (GAPs) in response to increased tension [156,157]. Rho is important for development of
fibrosis demonstrated by the inhibitory effect Rho and Rho kinase blockers on cardiac fibrosis [158].
The importance of FAK in cardiac fibrosis was recently demonstrated in vivo where application of a
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FAK inhibitor could inhibit myocardial fibrosis following myocardial infarction, although the trigger
for FAK activation in that study was suggested to be hypoxia and not mechanical stress per se [159].
Integrins also interact with other adhesion receptors. As such, the ectodomains of syndecans
have been found to promote integrin-mediated adhesion of mesenchymal cells, although the mode of
interaction is not known [160,161]. The only member of the integrin family known to directly interact
with syndecans (syndecan-1 and 4) via its cytoplasmic tail is α6β4 which is not expressed in cardiac
fibroblasts [162]. Direct cytoplasmic interaction between cardiac integrins and syndecans have not
been identified, although the existence of such interactions is a possibility given their overlapping
roles in regulation of fibroblast function.
5.2. Syndecan-4 Is Part of the Mechanosensory Apparatus of Fibroblasts
Syndecans comprise a family of four (syndecan-1 to 4). They are transmembrane proteins
extracellularly substituted with covalently attached, linear polysaccharide glycosaminoglycan (GAG)
chains that bind molecules in the ECM [163]. The core protein of syndecans is relatively small
(20–45 kDa). Despite their short cytoplasmic domain, it has become clear that syndecans have important
roles in intracellular signaling. Moreover, the binding of syndecan GAG chains to extracellular
molecules [164] and of the cytoplasmic domain to the cytoskeleton [165] make syndecans suited for
sensing and translating mechanical cues, affecting cells and tissues.
Although all four syndecans are expressed and regulated in heart diseases with increased wall
stress [111,166], only for syndecan-4 is there evidence suggesting a role in mechanotransduction in
the myocardium. Syndecan-4 is located at focal adhesions [163,167]. Its role in mechanotransduction
is derived from experiments in cultured fibroblasts that were mechanically stressed. By using
specific syndecan-4 antibodies it was shown that downstream intracellular signaling was increased
with mechanical activation in cells attached solely through syndecan-4 [168]. It was also shown
that presence of actin cytoskeletal filaments connected to focal adhesions was important for the
syndecan-4-induced response to mechanical stress. Moreover, Herum et al. [169] showed that cardiac
fibroblast expression of collagen I and III is dependent on syndecan-4, demonstrated using cardiac
fibroblasts from mice lacking syndecan-4. In vivo experiments on these mice showed that molecular
markers of myofibroblast differentiation were upregulated in wild-type mice, but not in mice lacking
syndecan-4, following pressure overload. Thus, in vivo and in vitro experiments clearly indicate
that syndecan-4 is part of a mechanosensory apparatus in cardiac fibroblasts, affecting myofibroblast
transitioning and collagen expression.
As indicated above, syndecan-4 induces fibroblast activation and differentiation through
regulation of intracellular signaling complexes and pathways. Although details on how syndecan-4
transduces mechanical stress into intracellular signals are still to be elucidated, it has been convincingly
shown that syndecan-4 is necessary for formation of focal adhesions [163,167], important sites for
mechanotransduction, located at the termini of cytoskeletal actin stress fibers. Recently, it was shown
that syndecan-4 was necessary for attachment of two important components of focal adhesions,
vinculin and F-actin, to the cytoskeleton [170]. Specific intracellular signals involved in regulating
syndecan-4 and its function are protein kinase C isoforms, phosphatidylinositol-(4,5)-bisphosphate and
the Rho-family of GTPases [163,167]. It is currently a priority in our group to identify the nodal points
in stress-induced syndecan-4 signaling and how it interacts with integrins to form focal adhesions,
thereby regulating further downstream signals leading to activation of fibroblasts.
A family of signaling molecules known to induce activation of fibroblasts is the nuclear
factor of activated T-cells (NFAT) family [153,154]. When active, the phosphatase calcineurin
dephosphorylates NFATc1-4 initiating nuclear translocation and expression of genes associated with
fibroblast differentiation. During increased cardiac and cellular stress, the calcineurin-NFAT pathway
was activated by syndecan-4 [171]. In fibroblasts, nuclear translocation of the NFATc4 isoform occurred
in response to cyclic mechanical stretch of fibroblasts in a calcineurin-dependent manner [169,172].
Blocking this pathway inhibited collagen production and myofibroblast differentiation [169].
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Calcineurin is regulated by calcium, and it was recently demonstrated that syndecan-4 controls calcium
homeostasis in focal adhesions. This is accomplished upon syndecan-4-ligand binding, which in turn
phosphorylates transient receptor potential canonical 7 (TRPC) 7 channels thereby stabilizing it in its
closed conformation [173]. It has also been shown that syndecan-4 mobilizes TRPC6 channels [174]
and that TRPC6 is required for activation of calcineurin/NFAT signaling and myofibroblast activation
in response to TGFβ [175]. Thus, emerging data indicate there is an important connection between
syndecan-4 and TRPC-calcium in regulating calcineurin-NFAT signaling and thus, fibroblast activation
and myofibroblast differentiation in response to mechanical stress.
In aortic stenosis patients and mouse models of myocardial infarction and pressure overload,
a role for full-length syndecan-4 in stress-induced fibrosis has been shown [109]. Syndecan-4 is
expressed in cardiac fibroblasts as well as myocytes and affect remodeling related to both cell
types in the pressure-overloaded hearts of mice and men [111]. Experimental studies manipulating
expression of syndecan-4 in vivo demonstrate its importance for stress-induced fibrosis. When pressure
overload is induced in syndecan-4 knock-out mice, they do not develop concentric hypertrophy as
wild-type mice [89,171], and importantly, myocardial stiffness is reduced owing to a reduced number
of myofibroblasts and attenuated collagen cross-linking [89]. Yet, it remains to be explored whether
targeting syndecan-4 and its associated pathways is a useful approach to prevent cardiac fibrosis and
diastolic dysfunction.
Interestingly, not only the full-length syndecan-4 protein is upregulated in the mechanically
stressed heart, but also the shedding of its extracellular domain is increased [111]. Shed syndecan-4 is
found in myocardial tissue biopsies from heart failure patients and in the coronary sinus of patients
with aortic stenosis, suggesting shedding from cardiac cells in response to persistent mechanical
stress [111]. In cardiac fibroblasts in culture, expression levels and shedding is regulated by interleukin
(IL) 1β, tumor necrosis factor (TNF) α and lipopolysaccharide (LPS)/TLR4 through a functional NFκB
site in its promoter [111]. Several proteases shed syndecan-4 ectodomains in culture, although the
relevant enzymes in the mechanically stressed heart remain to be elucidated.
Functionally, shedding of syndecan-4 in the heart represents an important aspect of syndecan-4
biology [109,163]. Cardiac fibroblasts in culture exposed to increased levels of shed syndecan-4 respond
with altered expression of ECM genes [106], favoring ECM degradation. Cardiac fibroblasts treated
with shed syndecan-4 fragments show reduced collagen I and III expression and reduced proliferation.
Thus, the shed fragment has opposite effects on collagen expression compared to full-length syndecan-4.
Accordingly, viral expression of the extracellular domain of syndecan-4 in the heart in vivo impaired
cardiac function and infarct healing [176]. Thus, controlling syndecan-4 shedding, which may be
possible by inhibiting receptors for IL-1β, TNFα or LPS, or through small molecules affecting central
shedding enzymes, may affect cardiac fibrosis.
Syndecan-1, 2 and 3 are not located in focal adhesions and have so far not convincingly been shown
to be involved in mechanotransduction. However, it has been shown that syndecan-1 is involved
in cardiac fibrosis [177–179]. It is upregulated following myocardial infarction [166] and pressure
overload [111], suggesting a role in the mechanical stress response of the heart. Although syndecan-1
may not be directly involved in mechanosensing, data clearly indicate that it is an essential mediator of
angiotensin-II-induced cardiac fibrosis. Syndecan-1 knock-out mice display attenuated cardiac fibrosis
upon angiotensin-II infusion. Moreover, it was shown that lack of syndecan-1 was associated with
reduced expression of collagen I and III and of connective tissue growth factor (CTGF), downstream
targets of TGFβ and YAP [180]. Thus, syndecan-1 might be involved in the mechano-regulation
of fibrosis through cross-talk with these signaling pathways. Interestingly, it has been shown that
circulating syndecan-1 correlates with markers of fibrosis and predicts clinical outcome in patients
with HFpEF [181], and thus syndecan-1 is suggested as a blood biomarker of fibrosis that may add
valuable diagnostic and prognostic information in HFpEF patients.
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5.3. Stretch-Activated Ion Channels (SACs); Functional Roles in Fibrosis Still to Be Explored
Another means of cell surface mechanotransduction is ion currents through mechanosensitive
channels. Although direct proof of mechanoactivation of these channels in cardiac fibroblasts is limited,
we will briefly review the current knowledge of this mechanism in myofibroblasts across different
organ systems that develop fibrosis, including heart, liver, lung and vasculature.
Cardiac fibroblasts are considered non-excitable cells, yet they do express several ion
channels including voltage-gated sodium channel Nav1.5 [182], ATP-sensitive potassium channels
(KATP) [183], calcium- activated big potassium channels (BKCa) [184], and non-selective cation
channels [175,185–187]. Mechanical cues can lead to opening of so-called stretch-activated ion
channels (SACs). TRPCs are candidates for the stretch-activated currents measured in cardiac
fibroblasts (Figure 3) [187–189]. In agreement, myofibroblast differentiation in response to TGFβ
and matrix stiffness depends on the presence of TRPC3 [190], TRPC6 [175] and transient receptor
potential vanilloid (TRPV) 4 [186,191] and involve Smad, MRTF-A and Akt signaling. Pharmacological
inhibition or genetic ablation of TRPC3 and TRPV4 prevent fibrosis in pressure-overloaded hearts [190]
and bleomycin-treated lungs [192], respectively, suggesting central roles for these channels in
pro-fibrotic signaling.
Although not yet studied in the heart, the most solid data for a stretch-activated channel is
Piezo1 [193] which is important for volume homeostasis in erythrocytes [194]. Interestingly, low levels
of Piezo1 mRNA are detected in mouse heart, and Piezo1 channel electrophysiological properties are
similar to that of endogenous cardiac cation non-selective stretch-activated channels. It will be exciting
to follow the future elucidation of the role of Piezo1 in cardiac fibroblasts.
6. Mechanotransduction by the Cytoskeleton: Actin’ on Nuclear Translocation
The cytoskeleton is a dynamic structural network essential for cell shape, stability and function,
and provides physical connectivity throughout the cell. The cytoskeletal pre-stress (the level of
isometric tension in the cytoskeleton), is constantly adjusted to create a balance between cytoskeletal
stiffness and ECM stiffness. Thus, ECM stiffness is a crucial regulator of cytoskeletal pre-stress [43,195]
which is largely determined by the formation of polymeric F-actin fibers from G-actin monomers.
The mechanisms whereby cells adjust pre-stress involve mechanotransduction signaling pathways
from surface molecules (e.g., integrins and syndecans) to the family of small Rho GTPases,
of which RhoA has been extensively studied [196]. RhoA interacts with, and thereby activates,
Rho kinase (ROCK) which phosphorylates several downstream targets involved in stress fiber
formation and dissociation, including LIM kinases (LIMK) and myosin light chain (MLC). LIMK will
phosphorylate cofilin, an actin depolymerizing factor which is inhibited by phosphorylation [197],
while phosphorylation of MLC directly increases actin contractility. The net result of RhoA activity is
enhanced actin fiber formation [196] which subsequently affects nuclear translocation of transcription
factors and thereby gene regulation.
6.1. Myocardin-Related Transcription Factors Are Liberated from Actin by Mechanical Stimulation
The myocardin-related transcription factors (MRTF) A and B bind to G-actin monomers present
in the cytosol under low tension conditions. In response to enhanced extracellular mechancal cues,
G-actin assembles into F-actin polymers thereby liberating MRTF from G-actin and allowing it to
enter the nucleus (Figure 3) [198–200]. Interestingly, nuclear shuttling of MRTF seems also to be
controlled by nuclear RhoA activity and its effector mDia2, which can shuttle between the nucleus
and cytoplasm. Nuclear actin polymerization, Rho and the mammalian homolog of Diaphanous
(mDia) all activate MRTF [201] which initiates gene transcription by acting as a cofactor for serum
response factor (SRF). SRF binds to CArG box elements in the promoter region of its target genes which
comprise a group of smooth muscle (and myofibroblast) marker genes including SMA and SM22.
Genetic knockout of MRTF-A reduces fibrosis and scar formation following myocardial infarction [202]
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and in bleomycin-induced pulmonary fibrosis [203]. Thus, MRTF-A is essential for myofibroblast
differentiation of development of cardiac fibrosis in response to mechanical cues.
6.2. Hippo Signaling Pathway Is Regulated by Cytoskeletal Dynamics
The Hippo signaling pathway has emerged as an important mechanotransduction pathway in
response to matrix stiffness [204–206]. Although the identity of the mechanosensor that initiates Hippo
signaling is not clear, cytoskeletal dynamics are central for pathway activity. Thus, inhibition of Rho
and disruption of F-actin results in pathway inactivation [207]. When Hippo signaling is absent,
the transcription coactivators YAP and its paralog TAZ (transcriptional coactivator with PDZ-binding
motif) can translocate between the cytoplasm and nucleus. YAP and TAZ are phosphorylated by
upstream kinases which, depending on the phosphorylation site, target them for degradation [208]
or retain them in the cytoplasm [209] through binding to cytoplasmic angiomotin. F-actin regulates
YAP activity by competitive binding to angiomotin thereby releasing YAP and allowing nuclear
translocation [209,210]. Since F-actin is regulated by the mechanical properties of the ECM, a stiff
matrix will promote nuclear translocation of YAP/TAZ while soft culturing conditions render them
cytoplasmic [35,211].
Although YAP and TAZ have not yet been studied in cardiac fibroblasts, nuclear localization
induces myofibroblast differentiation in liver [35,212], lung [211] and skin [213]. Mice lacking or
overexpressing constituents of the Hippo signaling pathway have demonstrated reduced and increased
fibrosis, respectively [214,215]. Likewise, knockdown or pharmacological inhibition of YAP/TAZ
delays wound healing [216] and prevents TGFβ-induced renal fibrosis [217]. Indeed, upregulation of
ECM genes, including CTGF has been found to depend on YAP/TAZ activity [180].
Since YAP and TAZ are transcriptional co-activators, they regulate gene expression through
interaction with transcription factors, including those of the TEA domain (TEAD) transcription
factor family [218]. Interestingly, direct interaction of YAP/TAZ with Smad3 of the TGFβ signaling
pathway has been shown in keratinocytes [219] and LLC-PK1 cells [220]. As such, YAP/TAZ activation
may comprise a mechanism for the established necessity of mechanical stress for TGFβ-induced
myofibroblast differentiation [221]. However, YAP/TAZ do not require TGFβ to induce pro-fibrotic
effects in response to matrix stiffness [35,211]. In line with this, TAZ was recently found to enhance
Smad3 sensitivety to the Acta2 (SMA) promoter, synergize with MRTF in binding to TEAD elements,
while antagonizing MRTF binding to the Acta2 promoter [220]. Thus TAZ seems to facilitate mechanical
and/or chemical pro-fibrotic signaling depending on the context.
Collectively, these results demonstrate the importance of the cytoskeleton in regulating the
pro-fibrotic gene program by acting on nuclear translocation of transcription regulators.
7. Nuclear Mechanosensing: Long-Distance Communication
The cytoskeleton provides a physical coupling from cell surface focal adhesions to protein
complexes in the nuclear membrane. This extraordinary structural connectivity throughout the
cell enables long-range force propagation from ECM structures directly to the nucleus thus allowing
propagation of mechanical signals more rapidly than by chemical diffusion or translocation-based
signaling [222].
The nucleus consists of the nuclear interior and the nuclear envelope, a continuous membrane
system comprising the outer and inner phospholipid bilayer membranes and the nuclear lamina
on the interior side of the membrane. The translation of mechanical cues into changes in cell
phenotype is accomplished by specialized proteins that are part of the linker of the nucleoskeleton and
cytoskeleton (LINC) complex that span the nuclear envelope bridging the cytoskeleton to the nuclear
lamina (Figure 3) [223]. This complex regulates transcription factors and chromatin structure in the
nucleus and thereby gene transcription [222,224]. Although studies examining cardiac fibroblasts
are sparse, data from fibroblast cell lines and mouse embryonic fibroblasts shed light on nuclear
mechanotransduction events most likely also relevant to cardiac fibroblasts.
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7.1. Linker of Nucleoskeleton and Cytoskeleton; A Complex for Nuclear Detection of Force
Starting from the cytosolic side, the LINC complex consists of transmembrane nesprin proteins
(nuclear envelope spectrin repeat protein) [225] that connect the cytoskeleton to the outer nuclear
membrane through binding of actin (for nesprin-1 and -2) and the intermediate filament binding
protein plectin (for nesprin-3) at their N-terminal [226,227]. Their C-terminal KASH (Klarsicht,
ANC-1, Syne Homology) domain is connected to the C-terminal Sad1-UNC (SUN) homology domains
of SUN proteins that protrude from the nuclear lumen into the perinuclear space between the
inner and outer nuclear membranes [228,229]. Importantly, SUN1 binds directly to lamin A [230]
and B [231] of the nuclear lamina thereby anchoring the LINC complex to the nucleoskeleton.
Lamins are specialized fibrous proteins that form the nuclear lamina and provide structural stability
to the nucleus. Other integral inner membrane proteins include emerin, MAN1, lamina-associated
polypeptide-emerin-MAN1 (LEM) 2, Samp1 and barrier-to-autointegration factor (BAF) which are
involved in nuclear organization and bind to lamin, DNA and various transcription factors [232,233].
Gene mutations, gene knockout and dominant negative expression of LINC complex proteins
have provided insight to their functions in mechanotransduction [234,235]. Mutations in the LMNA
gene encoding lamin A and C (resulting from alternative splicing), emerin and nesprins cause diseases
called laminopathies. The effects of these mutations are particularly apparent in tissues that are
under constant mechanical load, such as skeletal and cardiac muscle, resulting in muscular dystrophy
and dilated cardiomyopathy, respectively [236]. Fibroblasts from Lmna knockout mice show altered
proliferation, thus lamin A/C is likely important for fibroblast activation and possibly differentiation
into myofibroblasts [237]. In agreement, lamin A/C and emerin have been found to modulate actin
dynamics in mouse embryonic fibroblasts, regulating MRTF-A and SRF activity [238] which is essential
for myofibroblast differentiation in the heart [202].
Direct detection of force transduction across the LINC complex was recently accomplished using a
nesprin-2G FRET-based tension biosensor [239]. The force sensitivity of this biosensor is dependent on
actomyosin tension and cell shape, and LINC tension was reduced in fibroblasts from patients with the
LMNA genetic disorder Hutchinson-Gilford progeria syndrome with abnormal nucleus shape [239].
The mechanism whereby the LINC complex translates mechanical cues into gene regulatory
events, is poorly understood. However, there is evidence that direct interaction with transcription
factors may take place. Another possible mechanism is modification of nuclear import of gene
regulatory proteins [240] and export of mRNA through the nuclear pore complexes [241]. Of relevance
for fibrosis, TGFβ-induced nuclear translocation of the transcription factor Smad3 was hampered in
fibroblasts from nesprin-2 knockout mice [240].
The short isoform of transcriptional elongation factor bromodomain-containing protein 4 (Brd4)
is localized to the inner nuclear membrane where it associates with SUN proteins of the LINC complex
and binds to acetylated histones [242]. Brd4 expression levels correlate with ECM gene expression and
Brd4 is involved in gene regulation through RNA processing and chromatin modifications. Brd4 was
recently identified as a critical regulator of lung and liver fibrosis [243,244] and blocking Brd4 not
only prevents but also reverses fibrosis and myofibroblast differentiation of hepatic stellate cells [244].
Interestingly, Brd4 inhibition also reduces myocardial damage following infarction [245] suggesting a
role for Brd4 in the heart.
Finally there is evidence that the LINC complex regulates gene expression by modifying gene
accessibility and chromatin packaging. Indeed, SUN proteins bind directly to chromatin and are
central for chromosome organization during mitosis, reflected in SUN1 knockout mice being infertile
due to the inability to implement cell division [246]. However, the mechanism could also be of more
indirect character, regulating gene expression as a result of altered nuclear structure, shape and/or
stiffness. Indeed, substrate stiffness has been found to be important for LINC complex assembly [247].
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7.2. Nuclear Shape and Stiffness Is Associated with Cardiac Fibrosis
The nucleus itself has a stiffness in the range of 0.1 to 10 kPa [248] which is 2–10 times higher
than the cytoskeleton [249,250]. Changes in nuclear shape and stiffness are associated with changes in
gene expression and cell differentiation status. Thus it is likely that this physical parameter may play
a role in cardiac fibroblast differentiation into myofibroblasts. Indeed, there are strong correlations
between changes in nuclear shape and changes in fibroblast collagen synthesis in osteogenic cells [251].
Conversely, nuclear shape is affected by substrate stiffness as a result of stiffness-induced changes
in actomyosin tension being more round on soft substrates (0.4 kPa) and flattened on stiff substrates
(308 kPa) [252]. Nuclear shape was associated with cell responses to substrate stiffness including
cell spreading and migration speed. This “stiffness-sensing” was lost when the LINC complex was
disrupted suggesting that an intact nucleus-cytoskeleton connection is required for rigidity sensing.
The amount and localization of densely packed heterochromatin has been found to affect the
physical properties of the nucleus, providing structural stability and rigidity when located in the
nuclear periphery in proximity of the nuclear lamina. Likewise, the location of chromatin affects
packaging and thereby gene transcription, being more actively transcribed when located in the center
of the nucleus and silenced along the periphery [253]. Recently it was demonstrated that physical
deformation of the nucleus can rapidly (less than 15 s) modulate gene expression [254] by directly
affecting chromatin structure. It is likely that this is a ubiquitous and efficient way for cells to
accommodate transcriptional activity in response to external mechanical forces.
Lamins are essential for nuclear lamina structure and thereby nuclear stiffness. Cardiac cells
from Lmnaknock-out mice have disrupted nuclear lamina. This is also observed in mice
overexpressing the nucleosomal binding protein high mobility group nucleosome binding domain
5 (HMGN5) [255]. HMGN5 disrupts H1 histone and chromatin interaction and thereby reduces
chromatin compaction [256], suggesting a link between lamin and chromatin structure. Similar to
Lmna knock-out mice, HMGN5 overexpressing mice die before 8 weeks of age due to heart failure
characterized by ventricular wall thinning and substantial fibrosis [255]. Nuclei of cardiac fibroblasts
and myocytes in the maturing heart are exposed to increasing mechanical stress. Thus, the fragile
nucleus with reduced stiffness displays decompacted chromatin and nuclear blebbing, characteristics
of cell death. These observations emphasize the mechanosensitivity of nuclei and the importance of
nuclear structural integrity for cardiac cell adaption to mechanical forces.
Several questions remain regarding the detailed mechanisms of this fascinating long-range
communication system that enables cells to sense and translate extracellular mechanical cues into
transcriptional changes. Together with advanced molecular biology methods to study chromatin
dynamics and the rapidly growing knowledge of epigenetic gene regulatory mechanisms, a better
understanding of nuclear mechanotransduction, also in cardiac fibroblasts, is expected in the
near future.
8. Manipulating the Soft and Hard-Heartedness of Cardiac Fibroblasts
The consequences of cardiac fibrosis are widespread and detrimental and despite promising
results in animal models, clinical trials of anti-fibrotic therapies have been disappointing [11–15,257].
Drugs targeting the renin-angiotensin-aldosterone system, endothelin, inflammatory cytokines and
TGFβ have shown either modest regression of fibrosis, or adverse effects on the vasculature and
liver [257]. A beneficial effect of short-term infusion of the endogenous hormone relaxin in acute heart
failure has shown promise [258] and anti-fibrotic effects are clear in animal models of cardiac disease.
Here the challenge lies in the short half-life and costly production of this hormone. Furthermore,
most tested drugs are administered orally or through injections, i.e., are systemically administered,
increasing the chance of non-cardiac effects and hampering obtainment of sufficiently high cardiac
dosages without having toxic effects on other organs. These obstacles could potentially be overcome
by localized delivery or cardiac-specific targeting of future anti-fibrotic treatments.
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A more specific targeting of cardiac TGFβ might involve blocking mechanical activation of latent
TGFβ. This could potentially be accomplished by inhibiting αv integrin binding [60,70,187,259],
or inhibiting myofibroblast contraction using peptides that prevent the incorporation of SMA into
stress fibers [260]. For such an approach to be successful, directed targeting of cardiac myofibroblasts
is crucial since adhesion through integrins, and SMA fiber formation and contraction is an essential
part of normal smooth muscle cell function throughout the body.
Targeting mechanotransduction by the cytoskeleton also holds potential. Novel small molecule
inhibitors of Rho/MRTF-A signaling have been shown to prevent bleomycin-induced dermal fibrosis
in mice by oral administration, prevent scar tissue formation in a preclinical model of conjunctival
fibrosis [261] and prevent pulmonary fibrosis in two distinct mouse models [262]. Further optimization
of these compounds’ stability, solubility and potency has made them suitable for long-term treatment
of fibrosis. It will be exciting to see whether these will succeed in clinical trials and whether they could
be effective for treatment of fibrosis in the heart.
Verteporfin, a drug used to treat certain types of eye diseases, was recently found to inhibit
YAP [263] and dramatically reduce YAP/TAZ protein levels thereby preventing TGFβ-induced renal
fibrosis through smad2/3 [217]. Although the anti-fibrotic effect of verteporfin needs to be examined in
the heart, there might be therapeutic potential in repurposing this clinically approved and used drug.
One particular challenge using pharmacological inhibitors of mechanotransduction in the heart,
as described above, is the importance of these same pathways in cardiomyocytes. Thus, inhibition will
not only affect fibrosis, but likely also cardiomyocyte function and hypertrophic remodeling [264,265].
This is not necessarily a disadvantage, as balanced hypertrophic remodeling and fibrosis is key to
cardiac function, but it nevertheless represents a challenge when pursuing such therapeutic avenues.
Pharmacological treatments do not primarily interfere with the physical properties of the
extracellular matrix, which this review clearly emphasizes are crucial for cardiac fibroblast function
and phenotype. The increased matrix stiffness that accompanies fibrosis will favor the persistent
presence of pro-fibrotic activated cardiac fibroblasts, while a healthy cardiac fibroblast requires a
stiffness corresponding to that of the healthy heart [30,266]. Cumulating data suggest that the
myofibroblast phenotype is reversible [37,57,267–270], and that manipulating the stiffness of cell
culturing conditions is sufficient to induce myofibroblast reversion [37]. Thus, an alternative approach
to specific pharmacological targeting is the general targeting of mechanotransduction pathways by
manipulating tissue stiffness in vivo thereby promoting re-establishment of a healthy cardiac fibroblast
population in the fibrotic heart.
Recent advances in regenerative medicine and bioengineering has led to the development of
biomaterials of varying stiffness with clinical translational potential [271–274]. These include synthetic
hydrogels and naturally-derived matrices including decellularized cardiac porcine ECM [275] that can
be injected into wounded tissues to reduce wall stress and provide the tissue with a matrix stiffness
that promotes tissue repair. Indeed, following myocardial infarction in rats, injection of hydrogels into
the infarct region in the beginning of the fibrotic phase led to improved cardiomyocyte survival and
function, as well as reduced fibrosis both in the infarct and remote regions of the myocardium [272,276].
Whether a change in stiffness will alone be sufficient to reverse the cardiac myofibroblast
phenotype in vivo is yet to be studied. It may be that a combination of pharmacological and mechanical
approaches is needed. Indeed, anti-fibrotic drugs can be encapsulated in injectable hydrogels that
gradually release the drug upon hydrogel degradation enabling local and sustained delivery of
anti-fibrotic agents. This was recently demonstrated for an anti-fibrotic hepatic growth factor fragment
that reduced fibrosis following myocardial infarction in rats [277]. Moreover, drugs targeting the
mechanical memory of myofibroblasts may be useful in combination with injectable “soft” hydrogels.
It was recently shown that microRNA-21 is responsible for sustainment of a mechanical memory in
mesenchymal stem cells, and knockdown thereof promoted reversion of the pro-fibrotic phenotype
when used in combination with culturing on soft substrates [270].
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Injectable synthetic or native matrix-derived hydrogels are clinically attractive because of their
minimal invasiveness as they can be delivered to the heart as liquid through intramyocardial catheters
where after they polymerize into gels in the tissue. However, there are limitations and challenges to
this approach that need to be addressed. Importantly, safety in human patients has to be assessed
for translation from pre-clinical models. Although synthetic biomatrices are designed to mimic the
properties of the natural tissue, differences in structure and composition to the native ECM exist,
and native-derived hydrogels have been obtained from decellularized ECM from pigs, opening for
challenges related to species-differences
Even though successful treatment of fibrosis is currently lacking, there have been enormous
advances in this field over recent years providing substantially more insight into cardiac fibroblast
physiology and pathophysiology and opening for translation of pre-clinical findings that in the future
may offer benefit for patients. A better understanding of the importance of mechanical cues in
regulating the pro-fibrotic signaling in the heart is part of this foundation. It is likely that this increased
knowledge will enable manipulation and control of the soft- and hard-heartedness of cardiac fibroblasts
and hopefully, ultimately enable the prevention, reduction and reversion of cardiac fibrosis.
Acknowledgments: The authors are grateful for the funding from The Research Council of Norway, Anders Jahre’s
Fund for the Promotion of Science, the South-Eastern Regional Health Authority, Norway (K.M.H., I.G.L. and
G.C.), the Simon Fougner Hartmanns Family Fund (I.G.L. and G.C.), Denmark, and the European Commission
Marie Curie Actions’ COFUND program (K.M.H.). A.D.M is supported by California Institute of Regenerative
Medicine grant RT3-07899, by the National Biomedical Computation Resource (NIH grant P41 GM103426) and by
NIH R01 grants HL105242, HL121754, HL137100, and NIH U01 grants HL121754 and HL126273. Artwork by
Debbie Maizels, Zoobotanica Scientific Illustration.
Author Contributions: All authors contributed to the design, draft and revision of the work. The final version
was approved by all authors.
Conflicts of Interest: ADM is a co-founder of and has an equity interest in Insilicomed, Inc. He serves as a
scientific advisor to the company. Some research grants to ADM, including some of those acknowledged here,
have been identified for conflict of interest management based on the overall scope of the project and its potential
benefit to Insilicomed, Inc. ADM is required to disclose this relationship in publications acknowledging the grant
support, however the research subject matter and findings reported do not involve the company in any way
and they have no known relationship to the business activities or interests of the company. The terms of this
arrangement have been reviewed and approved by the University of California San Diego in accordance with its
conflict of interest policies. The other authors have no competing interests to declare.
References
1. Kong, P.; Christia, P.; Frangogiannis, N.G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 2014, 71,
549–574. [CrossRef] [PubMed]
2. Gyongyosi, M.; Winkler, J.; Ramos, I.; Do, Q.T.; Firat, H.; McDonald, K.; Gonzalez, A.; Thum, T.; Diez, J.;
Jaisser, F.; et al. Myocardial fibrosis: Biomedical research from bench to bedside. Eur. J. Heart Fail. 2017, 19,
177–191. [CrossRef] [PubMed]
3. Weber, G.F.; Zawaideh, S.; Hikita, S.; Kumar, V.A.; Cantor, H.; Ashkar, S. Phosphorylation-dependent
interaction of osteopontin with its receptors regulates macrophage migration and activation. J. Leukoc. Biol.
2002, 72, 752–761. [PubMed]
4. Weber, K.T.; Pick, R.; Jalil, J.E.; Janicki, J.S.; Carroll, E.P. Patterns of myocardial fibrosis. J. Mol. Cell. Cardiol.
1989, 21, 121–131. [CrossRef]
5. Weber, K.T.; Sun, Y.; Bhattacharya, S.K.; Ahokas, R.A.; Gerling, I.C. Myofibroblast-mediated mechanisms of
pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10, 15–26. [CrossRef] [PubMed]
6. Segura, A.M.; Frazier, O.H.; Buja, L.M. Fibrosis and heart failure. Heart Fail. Rev. 2014, 19, 173–185. [CrossRef]
[PubMed]
7. Shoulders, M.D.; Raines, R.T. Collagen structure and stability. Annu. Rev. Biochem. 2009, 78, 929–958.
[CrossRef] [PubMed]
8. Schellings, M.W.; Pinto, Y.M.; Heymans, S. Matricellular proteins in the heart: Possible role during stress and
remodeling. Cardiovasc. Res. 2004, 64, 24–31. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 18 of 31
9. Rienks, M.; Papageorgiou, A.P.; Frangogiannis, N.G.; Heymans, S. Myocardial extracellular matrix:
An ever-changing and diverse entity. Circ. Res. 2014, 114, 872–888. [CrossRef] [PubMed]
10. Tschope, C.; Lam, C.S. Diastolic heart failure: What we still don’t know. Looking for new concepts,
diagnostic approaches, and the role of comorbidities. Herz 2012, 37, 875–879. [CrossRef] [PubMed]
11. Van den Borne, S.W.; Diez, J.; Blankesteijn, W.M.; Verjans, J.; Hofstra, L.; Narula, J. Myocardial remodeling
after infarction: The role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7, 30–37. [CrossRef] [PubMed]
12. Camelliti, P.; Borg, T.K.; Kohl, P. Structural and functional characterisation of cardiac fibroblasts.
Cardiovasc. Res. 2005, 65, 40–51. [CrossRef] [PubMed]
13. Lajiness, J.D.; Conway, S.J. Origin, development, and differentiation of cardiac fibroblasts. J. Mol. Cell. Cardiol.
2014, 70, 2–8. [CrossRef] [PubMed]
14. Lindner, D.; Zietsch, C.; Becher, P.M.; Schulze, K.; Schultheiss, H.P.; Tschope, C.; Westermann, D. Differential
expression of matrix metalloproteases in human fibroblasts with different origins. Biochem. Res. Int. 2012.
[CrossRef] [PubMed]
15. Ivey, M.J.; Tallquist, M.D. Defining the cardiac fibroblast. Circ. J. 2016, 80, 2269–2276. [CrossRef] [PubMed]
16. Heymans, S.; Gonzalez, A.; Pizard, A.; Papageorgiou, A.P.; Lopez-Andres, N.; Jaisser, F.; Thum, T.; Zannad, F.;
Diez, J. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.
Eur. J. Heart Fail. 2015, 17, 764–771. [CrossRef] [PubMed]
17. Watson, C.J.; Phelan, D.; Collier, P.; Horgan, S.; Glezeva, N.; Cooke, G.; Xu, M.; Ledwidge, M.; McDonald, K.;
Baugh, J.A. Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses
to transforming growth factor β. Connect. Tissue Res. 2014, 55, 248–256. [CrossRef] [PubMed]
18. Rosenkranz, S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 2004, 63, 423–432.
[CrossRef] [PubMed]
19. Brilla, C.G.; Maisch, B.; Zhou, G.; Weber, K.T. Hormonal regulation of cardiac fibroblast function. Eur. Heart J.
1995, 16, 45–50. [CrossRef] [PubMed]
20. Mann, D.L. Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ. Res. 2015, 116,
1254–1268. [CrossRef] [PubMed]
21. Bryant, C.E.; Gay, N.J.; Heymans, S.; Sacre, S.; Schaefer, L.; Midwood, K.S. Advances in toll-like receptor
biology: Modes of activation by diverse stimuli. Crit. Rev. Biochem. Mol. Biol. 2015, 50, 359–379. [CrossRef]
[PubMed]
22. Krishnamurthy, A.; Villongco, C.T.; Chuang, J.; Frank, L.R.; Nigam, V.; Belezzuoli, E.; Stark, P.;
Krummen, D.E.; Narayan, S.; Omens, J.H.; et al. Patient-specific models of cardiac biomechanics.
J. Comput. Phys. 2013, 244, 4–21. [CrossRef] [PubMed]
23. Amundsen, B.H.; Helle-Valle, T.; Edvardsen, T.; Torp, H.; Crosby, J.; Lyseggen, E.; Stoylen, A.; Ihlen, H.;
Lima, J.A.; Smiseth, O.A.; et al. Noninvasive myocardial strain measurement by speckle tracking
echocardiography: Validation against sonomicrometry and tagged magnetic resonance imaging. J. Am.
Coll. Cardiol. 2006, 47, 789–793. [CrossRef] [PubMed]
24. Axel, L.; Montillo, A.; Kim, D. Tagged magnetic resonance imaging of the heart: A survey. Med. Image Anal.
2005, 9, 376–393. [CrossRef] [PubMed]
25. Van Putten, S.; Shafieyan, Y.; Hinz, B. Mechanical control of cardiac myofibroblasts. J. Mol. Cell. Cardiol. 2016,
93, 133–142. [CrossRef] [PubMed]
26. Goffin, J.M.; Pittet, P.; Csucs, G.; Lussi, J.W.; Meister, J.J.; Hinz, B. Focal adhesion size controls
tension-dependent recruitment of α-smooth muscle actin to stress fibers. J. Cell Biol. 2006, 172, 259–268.
[CrossRef] [PubMed]
27. Cui, Y.; Hameed, F.M.; Yang, B.; Lee, K.; Pan, C.Q.; Park, S.; Sheetz, M. Cyclic stretching of soft substrates
induces spreading and growth. Nat. Commun. 2015, 6, 6333. [CrossRef] [PubMed]
28. Pelham, R.J., Jr.; Wang, Y. Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc. Natl.
Acad. Sci. USA 1997, 94, 13661–13665. [CrossRef] [PubMed]
29. Zajaczkowski, M.B.; Cukierman, E.; Galbraith, C.G.; Yamada, K.M. Cell-matrix adhesions on poly(vinyl
alcohol) hydrogels. Tissue Eng. 2003, 9, 525–533. [CrossRef] [PubMed]
30. Engler, A.J.; Carag-Krieger, C.; Johnson, C.P.; Raab, M.; Tang, H.Y.; Speicher, D.W.; Sanger, J.W.; Sanger, J.M.;
Discher, D.E. Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: Scar-like rigidity
inhibits beating. J. Cell Sci. 2008, 121, 3794–3802. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 19 of 31
31. Berry, M.F.; Engler, A.J.; Woo, Y.J.; Pirolli, T.J.; Bish, L.T.; Jayasankar, V.; Morine, K.J.; Gardner, T.J.;
Discher, D.E.; Sweeney, H.L. Mesenchymal stem cell injection after myocardial infarction improves
myocardial compliance. Am. J. Physiol. Heart Circ. Physiol. 2006, 290, H2196–H2203. [CrossRef] [PubMed]
32. Solon, J.; Levental, I.; Sengupta, K.; Georges, P.C.; Janmey, P.A. Fibroblast adaptation and stiffness matching
to soft elastic substrates. Biophys. J. 2007, 93, 4453–4461. [CrossRef] [PubMed]
33. Tee, S.Y.; Fu, J.; Chen, C.S.; Janmey, P.A. Cell shape and substrate rigidity both regulate cell stiffness. Biophys. J.
2011, 100, L25–L27. [CrossRef] [PubMed]
34. Brown, X.Q.; Ookawa, K.; Wong, J.Y. Evaluation of polydimethylsiloxane scaffolds with
physiologically-relevant elastic moduli: Interplay of substrate mechanics and surface chemistry
effects on vascular smooth muscle cell response. Biomaterials 2005, 26, 3123–3129. [CrossRef] [PubMed]
35. Caliari, S.R.; Perepelyuk, M.; Cosgrove, B.D.; Tsai, S.J.; Lee, G.Y.; Mauck, R.L.; Wells, R.G.; Burdick, J.A.
Stiffening hydrogels for investigating the dynamics of hepatic stellate cell mechanotransduction during
myofibroblast activation. Sci. Rep. 2016, 6. [CrossRef] [PubMed]
36. Ondeck, M.G.; Engler, A.J. Mechanical characterization of a dynamic and tunable methacrylated hyaluronic
acid hydrogel. J. Biomech. Eng. 2016, 138, 0210031–0210036. [CrossRef] [PubMed]
37. Caliari, S.R.; Perepelyuk, M.; Soulas, E.M.; Lee, G.Y.; Wells, R.G.; Burdick, J.A. Gradually softening hydrogels
for modeling hepatic stellate cell behavior during fibrosis regression. Integr. Biol. 2016, 8, 720–728. [CrossRef]
[PubMed]
38. Throm Quinlan, A.M.; Sierad, L.N.; Capulli, A.K.; Firstenberg, L.E.; Billiar, K.L. Combining dynamic stretch
and tunable stiffness to probe cell mechanobiology in vitro. PLoS ONE 2011, 6. [CrossRef] [PubMed]
39. Herum, K.M.; Choppe, J.; Kumar, A.; Engler, A.J.; McCulloch, A.D. Mechanical regulation of cardiac fibroblast
pro-fibrotic phenotypes. Mol. Biol. Cell 2017. [CrossRef] [PubMed]
40. Lopez, B.; Querejeta, R.; Gonzalez, A.; Larman, M.; Diez, J. Collagen cross-linking but not collagen amount
associates with elevated filling pressures in hypertensive patients with stage c heart failure: Potential role of
lysyl oxidase. Hypertension 2012, 60, 677–683. [CrossRef] [PubMed]
41. Kasner, M.; Westermann, D.; Lopez, B.; Gaub, R.; Escher, F.; Kuhl, U.; Schultheiss, H.P.; Tschope, C. Diastolic
tissue doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and
normal ejection fraction. J. Am. Coll. Cardiol. 2011, 57, 977–985. [CrossRef] [PubMed]
42. Herrmann, K.L.; McCulloch, A.D.; Omens, J.H. Glycated collagen cross-linking alters cardiac mechanics
in volume-overload hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 2003, 284, H1277–H1284. [CrossRef]
[PubMed]
43. Wang, N.; Tolic-Norrelykke, I.M.; Chen, J.; Mijailovich, S.M.; Butler, J.P.; Fredberg, J.J.; Stamenovic, D.
Cell prestress. I. Stiffness and prestress are closely associated in adherent contractile cells. Am. J. Physiol.
Cell Physiol. 2002, 282, C606–C616. [CrossRef] [PubMed]
44. Mammoto, T.; Ingber, D.E. Mechanical control of tissue and organ development. Development 2010, 137,
1407–1420. [CrossRef] [PubMed]
45. LeGrice, I.J.; Takayama, Y.; Covell, J.W. Transverse shear along myocardial cleavage planes provides a
mechanism for normal systolic wall thickening. Circ. Res. 1995, 77, 182–193. [CrossRef] [PubMed]
46. Hinz, B.; Phan, S.H.; Thannickal, V.J.; Galli, A.; Bochaton-Piallat, M.L.; Gabbiani, G. The myofibroblast:
One function, multiple origins. Am. J. Pathol. 2007, 170, 1807–1816. [CrossRef] [PubMed]
47. Hinz, B. Formation and function of the myofibroblast during tissue repair. J. Investig. Dermatol. 2007, 127,
526–537. [CrossRef] [PubMed]
48. Hermans, K.C.; Daskalopoulos, E.P.; Blankesteijn, W.M. The janus face of myofibroblasts in the remodeling
heart. J. Mol. Cell. Cardiol. 2016, 91, 35–41. [CrossRef] [PubMed]
49. Tomasek, J.J.; Gabbiani, G.; Hinz, B.; Chaponnier, C.; Brown, R.A. Myofibroblasts and mechano-regulation of
connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 2002, 3, 349–363. [CrossRef] [PubMed]
50. Deb, A.; Ubil, E. Cardiac fibroblast in development and wound healing. J. Mol. Cell. Cardiol. 2014, 70, 47–55.
[CrossRef] [PubMed]
51. Pillai, I.C.; Li, S.; Romay, M.; Lam, L.; Lu, Y.; Huang, J.; Dillard, N.; Zemanova, M.; Rubbi, L.; Wang, Y.; et al.
Cardiac fibroblasts adopt osteogenic fates and can be targeted to attenuate pathological heart calcification.
Cell Stem Cell 2017, 20, 218–232. [CrossRef] [PubMed]
52. Moore-Morris, T.; Cattaneo, P.; Puceat, M.; Evans, S.M. Origins of cardiac fibroblasts. J. Mol. Cell. Cardiol.
2016, 91, 1–5. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 20 of 31
53. Zeisberg, E.M.; Tarnavski, O.; Zeisberg, M.; Dorfman, A.L.; McMullen, J.R.; Gustafsson, E.; Chandraker, A.;
Yuan, X.; Pu, W.T.; Roberts, A.B.; et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.
Nat. Med. 2007, 13, 952–961. [CrossRef] [PubMed]
54. Van Amerongen, M.J.; Bou-Gharios, G.; Popa, E.; van Ark, J.; Petersen, A.H.; van Dam, G.M.; van Luyn, M.J.;
Harmsen, M.C. Bone marrow-derived myofibroblasts contribute functionally to scar formation after
myocardial infarction. J. Pathol. 2008, 214, 377–386. [CrossRef] [PubMed]
55. Endo, J.; Sano, M.; Fujita, J.; Hayashida, K.; Yuasa, S.; Aoyama, N.; Takehara, Y.; Kato, O.; Makino, S.;
Ogawa, S.; et al. Bone marrow derived cells are involved in the pathogenesis of cardiac hypertrophy in
response to pressure overload. Circulation 2007, 116, 1176–1184. [CrossRef] [PubMed]
56. Diaz-Flores, L.; Gutierrez, R.; Madrid, J.F.; Varela, H.; Valladares, F.; Acosta, E.; Martin-Vasallo, P.;
Diaz-Flores, L., Jr. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated
mesenchymal cell niche. Histol Histopathol. 2009, 24, 909–969. [PubMed]
57. Kanisicak, O.; Khalil, H.; Ivey, M.J.; Karch, J.; Maliken, B.D.; Correll, R.N.; Brody, M.J.; Lin, S.-C.J.;
Aronow, B.J.; Tallquist, M.D.; et al. Genetic lineage tracing defines myofibroblast origin and function
in the injured heart. Nat. Commun. 2016, 7. [CrossRef] [PubMed]
58. Tallquist, M.D.; Molkentin, J.D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 2017.
[CrossRef] [PubMed]
59. Serini, G.; Bochaton-Piallat, M.L.; Ropraz, P.; Geinoz, A.; Borsi, L.; Zardi, L.; Gabbiani, G. The fibronectin
domain ed-a is crucial for myofibroblastic phenotype induction by transforming growth factor-β1. J. Cell Biol.
1998, 142, 873–881. [CrossRef] [PubMed]
60. Henderson, N.C.; Arnold, T.D.; Katamura, Y.; Giacomini, M.M.; Rodriguez, J.D.; McCarty, J.H.; Pellicoro, A.;
Raschperger, E.; Betsholtz, C.; Ruminski, P.G.; et al. Targeting of αv integrin identifies a core molecular
pathway that regulates fibrosis in several organs. Nat. Med. 2013, 19, 1617–1624. [CrossRef] [PubMed]
61. Kaur, H.; Takefuji, M.; Ngai, C.Y.; Carvalho, J.; Bayer, J.; Wietelmann, A.; Poetsch, A.; Hoelper, S.; Conway, S.J.;
Mollmann, H.; et al. Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac
remodeling in mice. Circ. Res. 2016, 118, 1906–1917. [CrossRef] [PubMed]
62. Lee, A.A.; Delhaas, T.; McCulloch, A.D.; Villarreal, F.J. Differential responses of adult cardiac fibroblasts to
in vitro biaxial strain patterns. J. Mol. Cell. Cardiol. 1999, 31, 1833–1843. [CrossRef] [PubMed]
63. Turner, N.A.; Porter, K.E. Function and fate of myofibroblasts after myocardial infarction.
Fibrogenesis Tissue Repair 2013, 6. [CrossRef] [PubMed]
64. Spinale, F.G.; Frangogiannis, N.G.; Hinz, B.; Holmes, J.W.; Kassiri, Z.; Lindsey, M.L. Crossing into the next
frontier of cardiac extracellular matrix research. Circ. Res. 2016, 119, 1040–1045. [CrossRef] [PubMed]
65. Katsumi, A.; Orr, A.W.; Tzima, E.; Schwartz, M.A. Integrins in mechanotransduction. J. Biol. Chem. 2004, 279,
12001–12004. [CrossRef] [PubMed]
66. Frangogiannis, N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92, 635–688.
[CrossRef] [PubMed]
67. Hinz, B. The extracellular matrix and transforming growth factor-β1: Tale of a strained relationship.
Matrix Biol. 2015, 47, 54–65. [CrossRef] [PubMed]
68. Sarrazy, V.; Koehler, A.; Chow, M.L.; Zimina, E.; Li, C.X.; Kato, H.; Caldarone, C.A.; Hinz, B. Integrins αvβ5
and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. Cardiovasc. Res. 2014,
102, 407–417. [CrossRef] [PubMed]
69. Wipff, P.J.; Hinz, B. Integrins and the activation of latent transforming growth factor β1—An intimate
relationship. Eur. J. Cell Biol. 2008, 87, 601–615. [CrossRef] [PubMed]
70. Hinz, B. It has to be the αv: Myofibroblast integrins activate latent TGF-β1. Nat. Med. 2013, 19, 1567–1568.
[CrossRef] [PubMed]
71. Shinde, A.V.; Frangogiannis, N.G. Fibroblasts in myocardial infarction: A role in inflammation and repair.
J. Mol. Cell. Cardiol. 2014, 70, 74–82. [CrossRef] [PubMed]
72. Kelsh, R.; You, R.; Horzempa, C.; Zheng, M.; McKeown-Longo, P.J. Regulation of the innate immune response
by fibronectin: Synergism between the iii-1 and eda domains. PLoS ONE 2014, 9. [CrossRef] [PubMed]
73. Biernacka, A.; Dobaczewski, M.; Frangogiannis, N.G. TGF-β signaling in fibrosis. Growth Factors 2011, 29,
196–202. [CrossRef] [PubMed]
74. Dobaczewski, M.; Chen, W.; Frangogiannis, N.G. Transforming growth factor TGF-β signaling in cardiac
remodeling. J. Mol. Cell. Cardiol. 2011, 51, 600–606. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 21 of 31
75. Jenkins, G. The role of proteases in transforming growth factor-β activation. Int. J. Biochem. Cell Biol. 2008,
40, 1068–1078. [CrossRef] [PubMed]
76. Zilberberg, L.; Todorovic, V.; Dabovic, B.; Horiguchi, M.; Courousse, T.; Sakai, L.Y.; Rifkin, D.B. Specificity
of latent TGF-β binding protein (LTBP) incorporation into matrix: Role of fibrillins and fibronectin.
J. Cell. Physiol. 2012, 227, 3828–3836. [CrossRef] [PubMed]
77. Robertson, I.B.; Horiguchi, M.; Zilberberg, L.; Dabovic, B.; Hadjiolova, K.; Rifkin, D.B. Latent TGF-β-binding
proteins. Matrix Biol. 2015, 47, 44–53. [CrossRef] [PubMed]
78. Nishimura, S.L. Integrin-mediated transforming growth factor-β activation, a potential therapeutic target in
fibrogenic disorders. Am. J. Pathol. 2009, 175, 1362–1370. [CrossRef] [PubMed]
79. Wipff, P.J.; Rifkin, D.B.; Meister, J.J.; Hinz, B. Myofibroblast contraction activates latent TGF-β1 from the
extracellular matrix. J. Cell Biol. 2007, 179, 1311–1323. [CrossRef] [PubMed]
80. Giacomini, M.M.; Travis, M.A.; Kudo, M.; Sheppard, D. Epithelial cells utilize cortical actin/myosin to
activate latent TGF-β through integrin αvβ6-dependent physical force. Exp. Cell Res. 2012, 318, 716–722.
[CrossRef] [PubMed]
81. Klingberg, F.; Chow, M.L.; Koehler, A.; Boo, S.; Buscemi, L.; Quinn, T.M.; Costell, M.; Alman, B.A.; Genot, E.;
Hinz, B. Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation. J. Cell Biol. 2014, 207,
283–297. [CrossRef] [PubMed]
82. Maeda, T.; Sakabe, T.; Sunaga, A.; Sakai, K.; Rivera, A.L.; Keene, D.R.; Sasaki, T.; Stavnezer, E.; Iannotti, J.;
Schweitzer, R.; et al. Conversion of mechanical force into TGF-β-mediated biochemical signals. Curr. Biol.
2011, 21, 933–941. [CrossRef] [PubMed]
83. Lopez, B.; Gonzalez, A.; Lindner, D.; Westermann, D.; Ravassa, S.; Beaumont, J.; Gallego, I.; Zudaire, A.;
Brugnolaro, C.; Querejeta, R.; et al. Osteopontin-mediated myocardial fibrosis in heart failure: A role for
lysyl oxidase? Cardiovasc. Res. 2013, 99, 111–120. [CrossRef] [PubMed]
84. Yang, J.; Savvatis, K.; Kang, J.S.; Fan, P.; Zhong, H.; Schwartz, K.; Barry, V.; Mikels-Vigdal, A.; Karpinski, S.;
Kornyeyev, D.; et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment.
Nat. Commun. 2016, 7. [CrossRef] [PubMed]
85. Huelsz-Prince, G.; Belkin, A.M.; VanBavel, E.; Bakker, E.N. Activation of extracellular transglutaminase 2 by
mechanical force in the arterial wall. J. Vasc. Res. 2013, 50, 383–395. [CrossRef] [PubMed]
86. Scarpellini, A.; Germack, R.; Lortat-Jacob, H.; Muramatsu, T.; Billett, E.; Johnson, T.; Verderio, E.A.
Heparan sulfate proteoglycans are receptors for the cell-surface trafficking and biological activity of
transglutaminase-2. J. Biol. Chem. 2009, 284, 18411–18423. [CrossRef] [PubMed]
87. Scarpellini, A.; Huang, L.; Burhan, I.; Schroeder, N.; Funck, M.; Johnson, T.S.; Verderio, E.A. Syndecan-4
knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.
J. Am. Soc. Nephrol. 2014, 25, 1013–1027. [CrossRef] [PubMed]
88. Wang, Z.; Collighan, R.J.; Pytel, K.; Rathbone, D.L.; Li, X.; Griffin, M. Characterization of heparin-binding
site of tissue transglutaminase: Its importance in cell surface targeting, matrix deposition, and cell signaling.
J. Biol. Chem. 2012, 287, 13063–13083. [CrossRef] [PubMed]
89. Herum, K.M.; Lunde, I.G.; Skrbic, B.; Louch, W.E.; Hasic, A.; Boye, S.; Unger, A.; Brorson, S.H.; Sjaastad, I.;
Tønnessen, T.; et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial
stiffness in the pressure-overloaded heart. Cardiovasc. Res. 2015, 106, 217–226. [CrossRef] [PubMed]
90. Lindsey, M.L.; Zouein, F.A.; Tian, Y.; Padmanabhan Iyer, R.; de Castro Bras, L.E. Osteopontin is proteolytically
processed by matrix metalloproteinase 9. Can. J. Physiol. Pharmacol. 2015, 93, 879–886. [CrossRef] [PubMed]
91. Slimani, H.; Charnaux, N.; Mbemba, E.; Saffar, L.; Vassy, R.; Vita, C.; Gattegno, L. Interaction of rantes with
syndecan-1 and syndecan-4 expressed by human primary macrophages. Biochim. Biophys. Acta 2003, 1617,
80–88. [CrossRef] [PubMed]
92. Bashkin, P.; Doctrow, S.; Klagsbrun, M.; Svahn, C.M.; Folkman, J.; Vlodavsky, I. Basic fibroblast growth factor
binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.
Biochemistry 1989, 28, 1737–1743. [CrossRef] [PubMed]
93. Bliksoen, M.; Mariero, L.H.; Ohm, I.K.; Haugen, F.; Yndestad, A.; Solheim, S.; Seljeflot, I.; Ranheim, T.;
Andersen, G.O.; Aukrust, P.; et al. Increased circulating mitochondrial DNA after myocardial infarction.
Int. J. Cardiol. 2012, 158, 132–134. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 22 of 31
94. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating
mitochondrial damps cause inflammatory responses to injury. Nature 2010, 464, 104–107. [CrossRef]
[PubMed]
95. Vabulas, R.M.; Ahmad-Nejad, P.; da Costa, C.; Miethke, T.; Kirschning, C.J.; Hacker, H.; Wagner, H.
Endocytosed hsp60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor
signaling pathway in innate immune cells. J. Biol. Chem. 2001, 276, 31332–31339. [CrossRef] [PubMed]
96. Quintana, F.J.; Cohen, I.R. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation.
J. Immunol. 2005, 175, 2777–2782. [CrossRef] [PubMed]
97. Chen, G.Y.; Nunez, G. Sterile inflammation: Sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10,
826–837. [CrossRef] [PubMed]
98. Tian, J.; Avalos, A.M.; Mao, S.Y.; Chen, B.; Senthil, K.; Wu, H.; Parroche, P.; Drabic, S.; Golenbock, D.;
Sirois, C.; et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated
by hmgb1 and rage. Nat. Immunol. 2007, 8, 487–496. [CrossRef] [PubMed]
99. Park, J.S.; Svetkauskaite, D.; He, Q.; Kim, J.Y.; Strassheim, D.; Ishizaka, A.; Abraham, E. Involvement of
toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 2004, 279,
7370–7377. [CrossRef] [PubMed]
100. Van Nieuwenhoven, F.A.; Hemmings, K.E.; Porter, K.E.; Turner, N.A. Combined effects of interleukin-1α
and transforming growth factor-β1 on modulation of human cardiac fibroblast function. Matrix Biol. 2013,
32, 399–406. [CrossRef] [PubMed]
101. Turner, N.A. Effects of interleukin-1 on cardiac fibroblast function: Relevance to post-myocardial infarction
remodelling. Vascul. Pharmacol. 2014, 60, 1–7. [CrossRef] [PubMed]
102. Maqbool, A.; Spary, E.J.; Manfield, I.W.; Ruhmann, M.; Zuliani-Alvarez, L.; Gamboa-Esteves, F.O.; Porter, K.E.;
Drinkhill, M.J.; Midwood, K.S.; Turner, N.A. Tenascin c upregulates interleukin-6 expression in human
cardiac myofibroblasts via toll-like receptor 4. World J. Cardiol. 2016, 8, 340–350. [CrossRef] [PubMed]
103. Frey, H.; Schroeder, N.; Manon-Jensen, T.; Iozzo, R.V.; Schaefer, L. Biological interplay between proteoglycans
and their innate immune receptors in inflammation. FEBS J. 2013, 280, 2165–2179. [CrossRef] [PubMed]
104. Engebretsen, K.V.; Lunde, I.G.; Strand, M.E.; Waehre, A.; Sjaastad, I.; Marstein, H.S.; Skrbic, B.; Dahl, C.P.;
Askevold, E.T.; Christensen, G.; et al. Lumican is increased in experimental and clinical heart failure, and its
production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. FEBS J. 2013, 280,
2382–2398. [CrossRef] [PubMed]
105. Engebretsen, K.V.; Waehre, A.; Bjørnstad, J.L.; Skrbic, B.; Sjaastad, I.; Behmen, D.; Marstein, H.S.; Yndestad, A.;
Aukrust, P.; Christensen, G.; et al. Decorin, lumican, and their gag chain-synthesizing enzymes are regulated
in myocardial remodeling and reverse remodeling in the mouse. J. Appl. Physiol. 2013, 114, 988–997.
[CrossRef] [PubMed]
106. Strand, M.E.; Aronsen, J.M.; Braathen, B.; Sjaastad, I.; Kvaløy, H.; Tønnessen, T.; Christensen, G.; Lunde, I.G.
Shedding of syndecan-4 promotes immune cell recruitment and mitigates cardiac dysfunction after
lipopolysaccharide challenge in mice. J. Mol. Cell. Cardiol. 2015, 88, 133–144. [CrossRef] [PubMed]
107. Taylor, K.R.; Trowbridge, J.M.; Rudisill, J.A.; Termeer, C.C.; Simon, J.C.; Gallo, R.L. Hyaluronan fragments
stimulate endothelial recognition of injury through TLR4. J. Biol. Chem. 2004, 279, 17079–17084. [CrossRef]
[PubMed]
108. Scheibner, K.A.; Lutz, M.A.; Boodoo, S.; Fenton, M.J.; Powell, J.D.; Horton, M.R. Hyaluronan fragments act
as an endogenous danger signal by engaging TLR2. J. Immunol. 2006, 177, 1272–1281. [CrossRef] [PubMed]
109. Lunde, I.G.; Herum, K.M.; Carlson, C.C.; Christensen, G. Syndecans in heart fibrosis. Cell Tissue Res. 2016,
365, 539–552. [CrossRef] [PubMed]
110. Waehre, A.; Vistnes, M.; Sjaastad, I.; Nygård, S.; Husberg, C.; Lunde, I.G.; Aukrust, P.; Yndestad, A.;
Vinge, L.E.; Behmen, D.; et al. Chemokines regulate small leucine-rich proteoglycans in the extracellular
matrix of the pressure-overloaded right ventricle. J. Appl. Physiol. 2012, 112, 1372–1382. [CrossRef] [PubMed]
111. Strand, M.E.; Herum, K.M.; Rana, Z.A.; Skrbic, B.; Askevold, E.T.; Dahl, C.P.; Vistnes, M.; Hasic, A.;
Kvaløy, H.; Sjaastad, I.; et al. Innate immune signaling induces expression and shedding of the heparan
sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the
pressure-overloaded heart. FEBS J. 2013, 280, 2228–2247. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 23 of 31
112. Melleby, A.O.; Strand, M.E.; Romaine, A.; Herum, K.M.; Skrbic, B.; Dahl, C.P.; Sjaastad, I.; Fiane, A.E.;
Filmus, J.; Christensen, G.; et al. The heparan sulfate proteoglycan glypican-6 is upregulated in the failing
heart, and regulates cardiomyocyte growth through ERK1/2 signaling. PLoS ONE 2016, 11. [CrossRef]
[PubMed]
113. Humphries, J.D.; Paul, N.R.; Humphries, M.J.; Morgan, M.R. Emerging properties of adhesion complexes:
What are they and what do they do? Trends Cell Biol. 2015, 25, 388–397. [CrossRef] [PubMed]
114. Schroer, A.K.; Merryman, W.D. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease.
J. Cell Sci. 2015, 128, 1865–1875. [CrossRef] [PubMed]
115. Hynes, R.O. Integrins: Bidirectional, allosteric signaling machines. Cell 2002, 110, 673–687. [CrossRef]
116. Harburger, D.S.; Calderwood, D.A. Integrin signalling at a glance. J. Cell Sci. 2009, 122, 159–163. [CrossRef]
[PubMed]
117. Zaidel-Bar, R.; Itzkovitz, S.; Ma’ayan, A.; Iyengar, R.; Geiger, B. Functional atlas of the integrin adhesome.
Nat. Cell Biol. 2007, 9, 858–867. [CrossRef] [PubMed]
118. Teoh, C.M.; Tam, J.K.; Tran, T. Integrin and gpcr crosstalk in the regulation of ASM contraction signaling in
asthma. J. Allergy 2012, 2012. [CrossRef] [PubMed]
119. Margadant, C.; Sonnenberg, A. Integrin-TGF-β crosstalk in fibrosis, cancer and wound healing. EMBO Rep.
2010, 11, 97–105. [CrossRef] [PubMed]
120. Mori, S.; Wu, C.Y.; Yamaji, S.; Saegusa, J.; Shi, B.; Ma, Z.; Kuwabara, Y.; Lam, K.S.; Isseroff, R.R.; Takada, Y.K.;
et al. Direct binding of integrin αvβ3 to FGF1 plays a role in FGF1 signaling. J. Biol. Chem. 2008, 283,
18066–18075. [CrossRef] [PubMed]
121. Agarwal, S.K. Integrins and cadherins as therapeutic targets in fibrosis. Front. Pharmacol. 2014, 5. [CrossRef]
[PubMed]
122. Kim, S.H.; Turnbull, J.; Guimond, S. Extracellular matrix and cell signalling: The dynamic cooperation of
integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011, 209, 139–151. [CrossRef] [PubMed]
123. MacKenna, D.A.; Dolfi, F.; Vuori, K.; Ruoslahti, E. Extracellular signal-regulated kinase and c-Jun
NH2-terminal kinase activation by mechanical stretch is integrin-dependent and matrix-specific in rat
cardiac fibroblasts. J. Clin. Investig. 1998, 101, 301–310. [CrossRef] [PubMed]
124. Chen, C.; Li, R.; Ross, R.S.; Manso, A.M. Integrins and integrin-related proteins in cardiac fibrosis. J. Mol.
Cell. Cardiol. 2016, 93, 162–174. [CrossRef] [PubMed]
125. Rodriguez, A.; Karen, J.; Gardner, H.; Gerdin, B.; Rubin, K.; Sundberg, C. Integrin α1β1 is involved in the
differentiation into myofibroblasts in adult reactive tissues in vivo. J. Cell. Mol. Med. 2009, 13, 3449–3462.
[CrossRef] [PubMed]
126. Kim, K.K.; Wei, Y.; Szekeres, C.; Kugler, M.C.; Wolters, P.J.; Hill, M.L.; Frank, J.A.; Brumwell, A.N.;
Wheeler, S.E.; Kreidberg, J.A.; et al. Epithelial cell α3β1 integrin links β-catenin and smad signaling
to promote myofibroblast formation and pulmonary fibrosis. J. Clin. Investig. 2009, 119, 213–224. [CrossRef]
[PubMed]
127. Wang, Z.; Collighan, R.J.; Gross, S.R.; Danen, E.H.; Orend, G.; Telci, D.; Griffin, M. RGD-independent cell
adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires
syndecan-4/2 α5β1 integrin co-signaling. J. Biol. Chem. 2010, 285, 40212–40229. [CrossRef] [PubMed]
128. Bouzeghrane, F.; Mercure, C.; Reudelhuber, T.L.; Thibault, G. α8β1 integrin is upregulated in myofibroblasts
of fibrotic and scarring myocardium. J. Mol. Cell. Cardiol. 2004, 36, 343–353. [CrossRef] [PubMed]
129. Sambandamoorthy, S.; Mathew-Steiner, S.; Varney, S.; Zuidema, J.M.; Gilbert, R.J.; Van De Water, L.;
LaFlamme, S.E. Matrix compliance and the regulation of cytokinesis. Biol. Open 2015, 4, 885–892. [CrossRef]
[PubMed]
130. Fujimura, T.; Moriwaki, S.; Imokawa, G.; Takema, Y. Crucial role of fibroblast integrins α2 and β1 in
maintaining the structural and mechanical properties of the skin. J. Dermatol. Sci. 2007, 45, 45–53. [CrossRef]
[PubMed]
131. Liu, S.; Leask, A. Integrin β1 is required for dermal homeostasis. J. Investig. Dermatol. 2013, 133, 899–906.
[CrossRef] [PubMed]
132. Riikonen, T.; Westermarck, J.; Koivisto, L.; Broberg, A.; Kahari, V.M.; Heino, J. Integrin α2β1 is a positive
regulator of collagenase (MMP-1) and collagen α1(I) gene expression. J. Biol. Chem. 1995, 270, 13548–13552.
[CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 24 of 31
133. Zhang, Y.; Lin, Z.; Foolen, J.; Schoen, I.; Santoro, A.; Zenobi-Wong, M.; Vogel, V. Disentangling the
multifactorial contributions of fibronectin, collagen and cyclic strain on mmp expression and extracellular
matrix remodeling by fibroblasts. Matrix Biol. 2014, 40, 62–72. [CrossRef] [PubMed]
134. Balasubramanian, S.; Quinones, L.; Kasiganesan, H.; Zhang, Y.; Pleasant, D.L.; Sundararaj, K.P.; Zile, M.R.;
Bradshaw, A.D.; Kuppuswamy, D. β3 Integrin in cardiac fibroblast is critical for extracellular matrix
accumulation during pressure overload hypertrophy in mouse. PLoS ONE 2012, 7. [CrossRef] [PubMed]
135. Luo, Y.; Sun, Y.; Zhu, Z.; Li, F. Is the change of integrin αvβ3 expression in the infarcted myocardium related
to the clinical outcome? Clin Nucl Med 2014, 39, 655–657. [CrossRef] [PubMed]
136. Roca-Cusachs, P.; Gauthier, N.C.; Del Rio, A.; Sheetz, M.P. Clustering of α5β1 integrins determines adhesion
strength whereas αvβ3 and talin enable mechanotransduction. Proc. Natl. Acad. Sci. USA 2009, 106,
16245–16250. [CrossRef] [PubMed]
137. Tiger, C.F.; Fougerousse, F.; Grundstrom, G.; Velling, T.; Gullberg, D. Alpha11β1 integrin is a receptor for
interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle
cells. Dev. Biol. 2001, 237, 116–129. [CrossRef] [PubMed]
138. Lu, N.; Carracedo, S.; Ranta, J.; Heuchel, R.; Soininen, R.; Gullberg, D. The human α11 integrin promoter
drives fibroblast-restricted expression in vivo and is regulated by TGF-β1 in a smad- and sp1-dependent
manner. Matrix Biol. 2010, 29, 166–176. [CrossRef] [PubMed]
139. Talior-Volodarsky, I.; Connelly, K.A.; Arora, P.D.; Gullberg, D.; McCulloch, C.A. Alpha11 integrin stimulates
myofibroblast differentiation in diabetic cardiomyopathy. Cardiovasc. Res. 2012, 96, 265–275. [CrossRef]
[PubMed]
140. Schulz, J.N.; Zeltz, C.; Sorensen, I.W.; Barczyk, M.; Carracedo, S.; Hallinger, R.; Niehoff, A.; Eckes, B.;
Gullberg, D. Reduced granulation tissue and wound strength in the absence of α11β1 integrin.
J. Investig. Dermatol. 2015, 135, 1435–1444. [CrossRef] [PubMed]
141. Carracedo, S.; Lu, N.; Popova, S.N.; Jonsson, R.; Eckes, B.; Gullberg, D. The fibroblast integrin α11β1 is
induced in a mechanosensitive manner involving activin a and regulates myofibroblast differentiation.
J. Biol. Chem. 2010, 285, 10434–10445. [CrossRef] [PubMed]
142. Zeltz, C.; Gullberg, D. The integrin-collagen connection—A glue for tissue repair? J. Cell Sci. 2016, 129,
653–664. [CrossRef] [PubMed]
143. Talior-Volodarsky, I.; Arora, P.D.; Wang, Y.; Zeltz, C.; Connelly, K.A.; Gullberg, D.; McCulloch, C.A. Glycated
collagen induces α11 integrin expression through TGF-β2 and smad3. J. Cell. Physiol. 2015, 230, 327–336.
[CrossRef] [PubMed]
144. Aronson, D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of
aging and diabetes. J. Hypertens. 2003, 21, 3–12. [CrossRef] [PubMed]
145. Navab, R.; Strumpf, D.; To, C.; Pasko, E.; Kim, K.S.; Park, C.J.; Hai, J.; Liu, J.; Jonkman, J.; Barczyk, M.; et al.
Integrin α11β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small
cell lung cancer. Oncogene 2016, 35, 1899–1908. [CrossRef] [PubMed]
146. Civitarese, R.A.; Talior-Volodarsky, I.; Desjardins, J.F.; Kabir, G.; Switzer, J.; Mitchell, M.; Kapus, A.;
McCulloch, C.A.; Gullberg, D.; Connelly, K.A. The α11 integrin mediates fibroblast-extracellular
matrix-cardiomyocyte interactions in health and disease. Am. J. Physiol. Heart Circ. Physiol. 2016, 311,
H96–H106. [CrossRef] [PubMed]
147. Schlaepfer, D.D.; Hunter, T. Integrin signalling and tyrosine phosphorylation: Just the faks? Trends Cell Biol.
1998, 8, 151–157. [CrossRef]
148. Critchley, D.R. Biochemical and structural properties of the integrin-associated cytoskeletal protein talin.
Annu. Rev. Biophys. 2009, 38, 235–254. [CrossRef] [PubMed]
149. Manso, A.M.; Li, R.; Monkley, S.J.; Cruz, N.M.; Ong, S.; Lao, D.H.; Koshman, Y.E.; Gu, Y.; Peterson, K.L.;
Chen, J.; et al. Talin1 has unique expression versus talin 2 in the heart and modifies the hypertrophic response
to pressure overload. J. Biol. Chem. 2013, 288, 4252–4264. [CrossRef] [PubMed]
150. Elosegui-Artola, A.; Oria, R.; Chen, Y.; Kosmalska, A.; Perez-Gonzalez, C.; Castro, N.; Zhu, C.; Trepat, X.;
Roca-Cusachs, P. Mechanical regulation of a molecular clutch defines force transmission and transduction in
response to matrix rigidity. Nat. Cell Biol. 2016, 18, 540–548. [CrossRef] [PubMed]
151. Carraher, C.L.; Schwarzbauer, J.E. Regulation of matrix assembly through rigidity-dependent fibronectin
conformational changes. J. Biol. Chem. 2013, 288, 14805–14814. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 25 of 31
152. Seong, J.; Tajik, A.; Sun, J.; Guan, J.L.; Humphries, M.J.; Craig, S.E.; Shekaran, A.; Garcia, A.J.; Lu, S.; Lin, M.Z.;
et al. Distinct biophysical mechanisms of focal adhesion kinase mechanoactivation by different extracellular
matrix proteins. Proc. Natl. Acad. Sci. USA 2013, 110, 19372–19377. [CrossRef] [PubMed]
153. Davis, J.; Molkentin, J.D. Myofibroblasts: Trust your heart and let fate decide. J. Mol. Cell. Cardiol. 2014, 70,
9–18. [CrossRef] [PubMed]
154. Lighthouse, J.K.; Small, E.M. Transcriptional control of cardiac fibroblast plasticity. J. Mol. Cell. Cardiol. 2016,
91, 52–60. [CrossRef] [PubMed]
155. Molkentin, J.D.; Bugg, D.; Ghearing, N.; Dorn, L.E.; Kim, P.; Sargent, M.A.; Gunaje, J.; Otsu, K.; Davis, J.M.
Fibroblast-specific genetic manipulation of p38 MAPK in vivo reveals its central regulatory role in fibrosis.
Circulation 2017. [CrossRef] [PubMed]
156. Rossman, K.L.; Der, C.J.; Sondek, J. Gef means go: Turning on Rho GTPases with guanine
nucleotide-exchange factors. Nat. Rev. Mol. Cell Biol. 2005, 6, 167–180. [CrossRef] [PubMed]
157. Guilluy, C.; Swaminathan, V.; Garcia-Mata, R.; O’Brien, E.T.; Superfine, R.; Burridge, K. The Rho GEFs
LARG and GEF-H1 regulate the mechanical response to force on integrins. Nat. Cell Biol. 2011, 13, 722–727.
[CrossRef] [PubMed]
158. Shimizu, T.; Liao, J.K. Rho kinases and cardiac remodeling. Circ. J. 2016, 80, 1491–1498. [CrossRef] [PubMed]
159. Zhang, J.; Fan, G.; Zhao, H.; Wang, Z.; Li, F.; Zhang, P.; Zhang, J.; Wang, X.; Wang, W. Targeted inhibition of
focal adhesion kinase attenuates cardiac fibrosis and preserves heart function in adverse cardiac remodeling.
Sci. Rep. 2017, 7. [CrossRef] [PubMed]
160. McQuade, K.J.; Beauvais, D.M.; Burbach, B.J.; Rapraeger, A.C. Syndecan-1 regulates αvβ5 integrin activity
in b82l fibroblasts. J. Cell Sci. 2006, 119, 2445–2456. [CrossRef] [PubMed]
161. Whiteford, J.R.; Behrends, V.; Kirby, H.; Kusche-Gullberg, M.; Muramatsu, T.; Couchman, J.R. Syndecans
promote integrin-mediated adhesion of mesenchymal cells in two distinct pathways. Exp. Cell Res. 2007, 313,
3902–3913. [CrossRef] [PubMed]
162. Kawano, H.; Cody, R.J.; Graf, K.; Goetze, S.; Kawano, Y.; Schnee, J.; Law, R.E.; Hsueh, W.A. Angiotensin II
enhances integrin and α-actinin expression in adult rat cardiac fibroblasts. Hypertension 2000, 35, 273–279.
[CrossRef] [PubMed]
163. Couchman, J.R. Transmembrane signaling proteoglycans. Annu. Rev. Cell Dev. Biol. 2010, 26, 89–114.
[CrossRef] [PubMed]
164. Li, L.; Chaikof, E.L. Mechanical stress regulates syndecan-4 expression and redistribution in vascular smooth
muscle cells. Arterioscler. Thromb. Vasc. Biol. 2002, 22, 61–68. [CrossRef] [PubMed]
165. Greene, D.K.; Tumova, S.; Couchman, J.R.; Woods, A. Syndecan-4 associates with α-actinin. J. Biol. Chem.
2003, 278, 7617–7623. [CrossRef] [PubMed]
166. Finsen, A.V.; Woldbaek, P.R.; Li, J.; Wu, J.; Lyberg, T.; Tonnessen, T.; Christensen, G. Increased syndecan
expression following myocardial infarction indicates a role in cardiac remodeling. Physiol. Genom. 2004, 16,
301–308. [CrossRef] [PubMed]
167. Morgan, M.R.; Humphries, M.J.; Bass, M.D. Synergistic control of cell adhesion by integrins and syndecans.
Nat. Rev. Mol. Cell Biol. 2007, 8, 957–969. [CrossRef] [PubMed]
168. Bellin, R.M.; Kubicek, J.D.; Frigault, M.J.; Kamien, A.J.; Steward, R.L., Jr.; Barnes, H.M.; Digiacomo, M.B.;
Duncan, L.J.; Edgerly, C.K.; Morse, E.M.; et al. Defining the role of Syndecan-4 in mechanotransduction using
surface-modification approaches. Proc. Natl. Acad. Sci. USA 2009, 106, 22102–22107. [CrossRef] [PubMed]
169. Herum, K.M.; Lunde, I.G.; Skrbic, B.; Florholmen, G.; Behmen, D.; Sjaastad, I.; Carlson, C.R.; Gomez, M.F.;
Christensen, G. Syndecan-4 signaling via nfat regulates extracellular matrix production and cardiac
myofibroblast differentiation in response to mechanical stress. J. Mol. Cell. Cardiol. 2013, 54, 73–81.
[CrossRef] [PubMed]
170. Cavalheiro, R.P.; Lima, M.A.; Jarrouge-Boucas, T.R.; Viana, G.M.; Lopes, C.C.; Coulson-Thomas, V.J.;
Dreyfuss, J.L.; Yates, E.A.; Tersariol, I.L.; Nader, H.B. Coupling of vinculin to F-actin demands syndecan-4
proteoglycan. Matrix Biol. 2017. [CrossRef] [PubMed]
171. Finsen, A.V.; Lunde, I.G.; Sjaastad, I.; Østli, E.K.; Lyngra, M.; Jarstadmarken, H.O.; Hasic, A.; Nygård, S.;
Wilcox-Adelman, S.A.; Goetinck, P.F.; et al. Syndecan-4 is essential for development of concentric myocardial
hypertrophy via stretch-induced activation of the calcineurin-NFAT pathway. PLoS ONE 2011, 6. [CrossRef]
[PubMed]
J. Clin. Med. 2017, 6, 53 26 of 31
172. Samarel, A.M. Syndecan-4: A component of the mechanosensory apparatus of cardiac fibroblasts. J. Mol.
Cell. Cardiol. 2013, 56, 19–21. [CrossRef] [PubMed]
173. Gopal, S.; Søgaard, P.; Multhaupt, H.A.; Pataki, C.; Okina, E.; Xian, X.; Pedersen, M.E.; Stevens, T.;
Griesbeck, O.; Park, P.W.; et al. Transmembrane proteoglycans control stretch-activated channels to set
cytosolic calcium levels. J. Cell Biol. 2015, 210, 1199–1211. [CrossRef] [PubMed]
174. Kim, E.Y.; Roshanravan, H.; Dryer, S.E. Syndecan-4 ectodomain evokes mobilization of podocyte TRPC6
channels and their associated pathways: An essential role for integrin signaling. Biochim. Biophys. Acta 2015,
1853, 2610–2620. [CrossRef] [PubMed]
175. Davis, J.; Burr, A.R.; Davis, G.F.; Birnbaumer, L.; Molkentin, J.D. A TRPC6-dependent pathway for
myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 2012, 23, 705–715. [CrossRef]
[PubMed]
176. Matsui, Y.; Ikesue, M.; Danzaki, K.; Morimoto, J.; Sato, M.; Tanaka, S.; Kojima, T.; Tsutsui, H.; Uede, T.
Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction. Circ. Res. 2011, 108,
1328–1339. [CrossRef] [PubMed]
177. Frangogiannis, N.G. Syndecan-1: A critical mediator in cardiac fibrosis. Hypertension 2010, 55, 233–235.
[CrossRef] [PubMed]
178. Vanhoutte, D.; Schellings, M.W.; Gotte, M.; Swinnen, M.; Herias, V.; Wild, M.K.; Vestweber, D.;
Chorianopoulos, E.; Cortes, V.; Rigotti, A.; et al. Increased expression of syndecan-1 protects against
cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007, 115, 475–482. [CrossRef]
[PubMed]
179. Schellings, M.W.; Vanhoutte, D.; van Almen, G.C.; Swinnen, M.; Leenders, J.J.; Kubben, N.; van Leeuwen, R.E.;
Hofstra, L.; Heymans, S.; Pinto, Y.M. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis.
Hypertension 2010, 55, 249–256. [CrossRef] [PubMed]
180. Shimomura, T.; Miyamura, N.; Hata, S.; Miura, R.; Hirayama, J.; Nishina, H. The pdz-binding motif of
yes-associated protein is required for its co-activation of tead-mediated CTGF transcription and oncogenic
cell transforming activity. Biochem. Biophys. Res. Commun. 2014, 443, 917–923. [CrossRef] [PubMed]
181. Tromp, J.; van der Pol, A.; Klip, I.T.; de Boer, R.A.; Jaarsma, T.; van Gilst, W.H.; Voors, A.A.;
van Veldhuisen, D.J.; van der Meer, P. Fibrosis marker syndecan-1 and outcome in patients with heart
failure with reduced and preserved ejection fraction. Circ. Heart Fail. 2014, 7, 457–462. [CrossRef] [PubMed]
182. Chatelier, A.; Mercier, A.; Tremblier, B.; Theriault, O.; Moubarak, M.; Benamer, N.; Corbi, P.; Bois, P.;
Chahine, M.; Faivre, J.F. A distinct de novo expression of Nav1.5 sodium channels in human atrial fibroblasts
differentiated into myofibroblasts. J. Physiol. 2012, 590, 4307–4319. [CrossRef] [PubMed]
183. Benamer, N.; Vasquez, C.; Mahoney, V.M.; Steinhardt, M.J.; Coetzee, W.A.; Morley, G.E. Fibroblast katp
currents modulate myocyte electrophysiology in infarcted hearts. Am. J. Physiol. Heart Circ. Physiol. 2013,
304, H1231–H1239. [CrossRef] [PubMed]
184. Wang, Y.J.; Sung, R.J.; Lin, M.W.; Wu, S.N. Contribution of BKCa-channel activity in human cardiac fibroblasts
to electrical coupling of cardiomyocytes-fibroblasts. J. Membr. Biol. 2006, 213, 175–185. [CrossRef] [PubMed]
185. Rose, R.A.; Hatano, N.; Ohya, S.; Imaizumi, Y.; Giles, W.R. C-type natriuretic peptide activates a non-selective
cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide c receptor-mediated signalling.
J. Physiol. 2007, 580, 255–274. [CrossRef] [PubMed]
186. Adapala, R.K.; Thoppil, R.J.; Luther, D.J.; Paruchuri, S.; Meszaros, J.G.; Chilian, W.M.; Thodeti, C.K. Trpv4
channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals. J. Mol.
Cell. Cardiol. 2013, 54, 45–52. [CrossRef] [PubMed]
187. Reed, A.; Kohl, P.; Peyronnet, R. Molecular candidates for cardiac stretch-activated ion channels. Glob. Cardiol.
Sci. Pract. 2014, 2014, 9–25. [CrossRef] [PubMed]
188. Kamkin, A.; Kirischuk, S.; Kiseleva, I. Single mechano-gated channels activated by mechanical deformation
of acutely isolated cardiac fibroblasts from rats. Acta Physiol. 2010, 199, 277–292. [CrossRef] [PubMed]
189. Rog-Zielinska, E.A.; Norris, R.A.; Kohl, P.; Markwald, R. The living scar—Cardiac fibroblasts and the injured
heart. Trends Mol. Med. 2016, 22, 99–114. [CrossRef] [PubMed]
190. Numaga-Tomita, T.; Kitajima, N.; Kuroda, T.; Nishimura, A.; Miyano, K.; Yasuda, S.; Kuwahara, K.; Sato, Y.;
Ide, T.; Birnbaumer, L.; et al. TRPC3-GEF-H1 axis mediates pressure overload-induced cardiac fibrosis.
Sci. Rep. 2016, 6. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 27 of 31
191. Sharma, S.; Goswami, R.; Merth, M.; Cohen, J.; Lei, K.Y.; Zhang, D.X.; Rahaman, S.O. TRPV4 ion channel is a
novel regulator of dermal myofibroblast differentiation. Am. J. Physiol. Cell Physiol. 2017, 312, C562–C572.
[CrossRef] [PubMed]
192. Rahaman, S.O.; Grove, L.M.; Paruchuri, S.; Southern, B.D.; Abraham, S.; Niese, K.A.; Scheraga, R.G.;
Ghosh, S.; Thodeti, C.K.; Zhang, D.X.; et al. TRPV4 mediates myofibroblast differentiation and pulmonary
fibrosis in mice. J. Clin. Investig. 2014, 124, 5225–5238. [CrossRef] [PubMed]
193. Coste, B.; Mathur, J.; Schmidt, M.; Earley, T.J.; Ranade, S.; Petrus, M.J.; Dubin, A.E.; Patapoutian, A. Piezo1
and piezo2 are essential components of distinct mechanically activated cation channels. Science 2010, 330,
55–60. [CrossRef] [PubMed]
194. Faucherre, A.; Kissa, K.; Nargeot, J.; Mangoni, M.E.; Jopling, C. Piezo1 plays a role in erythrocyte volume
homeostasis. Haematologica 2014, 99, 70–75. [CrossRef] [PubMed]
195. Ingber, D.E.; Wang, N.; Stamenovic, D. Tensegrity, cellular biophysics, and the mechanics of living systems.
Rep. Prog. Phys. 2014, 77. [CrossRef] [PubMed]
196. Amano, M.; Nakayama, M.; Kaibuchi, K. Rho-kinase/rock: A key regulator of the cytoskeleton and cell
polarity. Cytoskeleton 2010, 67, 545–554. [CrossRef] [PubMed]
197. Maekawa, M.; Ishizaki, T.; Boku, S.; Watanabe, N.; Fujita, A.; Iwamatsu, A.; Obinata, T.; Ohashi, K.;
Mizuno, K.; Narumiya, S. Signaling from rho to the actin cytoskeleton through protein kinases rock and
lim-kinase. Science 1999, 285, 895–898. [CrossRef] [PubMed]
198. Miralles, F.; Posern, G.; Zaromytidou, A.I.; Treisman, R. Actin dynamics control srf activity by regulation of
its coactivator mal. Cell 2003, 113, 329–342. [CrossRef]
199. Kuwahara, K.; Barrientos, T.; Pipes, G.C.; Li, S.; Olson, E.N. Muscle-specific signaling mechanism that links
actin dynamics to serum response factor. Mol. Cell. Biol. 2005, 25, 3173–3181. [CrossRef] [PubMed]
200. Mouilleron, S.; Langer, C.A.; Guettler, S.; McDonald, N.Q.; Treisman, R. Structure of a pentavalent
G-actin*MRTF-A complex reveals how G-actin controls nucleocytoplasmic shuttling of a transcriptional
coactivator. Sci. Signal. 2011, 4. [CrossRef] [PubMed]
201. Staus, D.P.; Weise-Cross, L.; Mangum, K.D.; Medlin, M.D.; Mangiante, L.; Taylor, J.M.; Mack, C.P. Nuclear
Rhoa signaling regulates MRTF-dependent smc-specific transcription. Am. J. Physiol. Heart Circ. Physiol.
2014, 307, H379–H390. [CrossRef] [PubMed]
202. Small, E.M.; Thatcher, J.E.; Sutherland, L.B.; Kinoshita, H.; Gerard, R.D.; Richardson, J.A.; Dimaio, J.M.;
Sadek, H.; Kuwahara, K.; Olson, E.N. Myocardin-related transcription factor-a controls myofibroblast
activation and fibrosis in response to myocardial infarction. Circ. Res. 2010, 107, 294–304. [CrossRef]
[PubMed]
203. Zhou, Y.; Huang, X.; Hecker, L.; Kurundkar, D.; Kurundkar, A.; Liu, H.; Jin, T.H.; Desai, L.; Bernard, K.;
Thannickal, V.J. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental
pulmonary fibrosis. J. Clin. Investig. 2013, 123, 1096–1108. [CrossRef] [PubMed]
204. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giulitti, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.;
Forcato, M.; Bicciato, S.; et al. Role of yap/taz in mechanotransduction. Nature 2011, 474, 179–183. [CrossRef]
[PubMed]
205. Aragona, M.; Panciera, T.; Manfrin, A.; Giulitti, S.; Michielin, F.; Elvassore, N.; Dupont, S.; Piccolo, S.
A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing
factors. Cell 2013, 154, 1047–1059. [CrossRef] [PubMed]
206. Codelia, V.A.; Sun, G.; Irvine, K.D. Regulation of yap by mechanical strain through JNK and hippo signaling.
Curr. Biol. 2014, 24, 2012–2017. [CrossRef] [PubMed]
207. Muehlich, S.; Rehm, M.; Ebenau, A.; Goppelt-Struebe, M. Synergistic induction of CTGF by cytochalasin D
and TGFβ-1 in primary human renal epithelial cells: Role of transcriptional regulators MK11, YAP/TAZ and
Smad2/3. Cell. Signal. 2017, 29, 31–40. [CrossRef] [PubMed]
208. Dong, J.; Feldmann, G.; Huang, J.; Wu, S.; Zhang, N.; Comerford, S.A.; Gayyed, M.F.; Anders, R.A.;
Maitra, A.; Pan, D. Elucidation of a universal size-control mechanism in drosophila and mammals. Cell 2007,
130, 1120–1133. [CrossRef] [PubMed]
209. Dai, X.; She, P.; Chi, F.; Feng, Y.; Liu, H.; Jin, D.; Zhao, Y.; Guo, X.; Jiang, D.; Guan, K.L.; et al. Phosphorylation
of angiomotin by LATS1/2 kinases inhibits f-actin binding, cell migration, and angiogenesis. J. Biol. Chem.
2013, 288, 34041–34051. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 28 of 31
210. Mana-Capelli, S.; Paramasivam, M.; Dutta, S.; McCollum, D. Angiomotins link f-actin architecture to hippo
pathway signaling. Mol. Biol. Cell 2014, 25, 1676–1685. [CrossRef] [PubMed]
211. Liu, F.; Lagares, D.; Choi, K.M.; Stopfer, L.; Marinkovic, A.; Vrbanac, V.; Probst, C.K.; Hiemer, S.E.; Sisson, T.H.;
Horowitz, J.C.; et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J.
Physiol. Lung Cell Mol. Physiol. 2015, 308, L344–L357. [CrossRef] [PubMed]
212. Mannaerts, I.; Leite, S.B.; Verhulst, S.; Claerhout, S.; Eysackers, N.; Thoen, L.F.; Hoorens, A.; Reynaert, H.;
Halder, G.; van Grunsven, L.A. The hippo pathway effector YAP controls mouse hepatic stellate cell
activation. J. Hepatol. 2015, 63, 679–688. [CrossRef] [PubMed]
213. Piersma, B.; de Rond, S.; Werker, P.M.; Boo, S.; Hinz, B.; van Beuge, M.M.; Bank, R.A. YAP1 is a driver
of myofibroblast differentiation in normal and diseased fibroblasts. Am. J. Pathol. 2015, 185, 3326–3337.
[CrossRef] [PubMed]
214. Mitani, A.; Nagase, T.; Fukuchi, K.; Aburatani, H.; Makita, R.; Kurihara, H. Transcriptional coactivator with
PDZ-binding motif is essential for normal alveolarization in mice. Am. J. Respir. Crit. Care Med. 2009, 180,
326–338. [CrossRef] [PubMed]
215. Zhou, J. An emerging role for Hippo-YAP signaling in cardiovascular development. J. Biomed. Res. 2014, 28,
251–254. [PubMed]
216. Lee, M.J.; Ran Byun, M.; Furutani-Seiki, M.; Hong, J.H.; Jung, H.S. Yap and taz regulate skin wound healing.
J. Investig. Dermatol. 2014, 134, 518–525. [CrossRef] [PubMed]
217. Szeto, S.G.; Narimatsu, M.; Lu, M.; He, X.; Sidiqi, A.M.; Tolosa, M.F.; Chan, L.; De Freitas, K.; Bialik, J.F.;
Majumder, S.; et al. YAP/TAZ are mechanoregulators of TGF-β-smad signaling and renal fibrogenesis. J. Am.
Soc. Nephrol. 2016. [CrossRef] [PubMed]
218. Zhao, B.; Ye, X.; Yu, J.; Li, L.; Li, W.; Li, S.; Yu, J.; Lin, J.D.; Wang, C.Y.; Chinnaiyan, A.M.; et al. Tead mediates
YAP-dependent gene induction and growth control. Genes Dev. 2008, 22, 1962–1971. [CrossRef] [PubMed]
219. Grannas, K.; Arngarden, L.; Lonn, P.; Mazurkiewicz, M.; Blokzijl, A.; Zieba, A.; Soderberg, O. Crosstalk
between hippo and TGFB: Subcellular localization of YAP/TAZ/SMAD complexes. J. Mol. Biol. 2015, 427,
3407–3415. [CrossRef] [PubMed]
220. Speight, P.; Kofler, M.; Szaszi, K.; Kapus, A. Context-dependent switch in chemo/mechanotransduction
via multilevel crosstalk among cytoskeleton-regulated MRTF and TAZ and TGFβ-regulated SMAD3.
Nat. Commun. 2016, 7. [CrossRef] [PubMed]
221. Chan, M.W.; Hinz, B.; McCulloch, C.A. Mechanical induction of gene expression in connective tissue cells.
Methods Cell Biol. 2010, 98, 178–205. [PubMed]
222. Wang, N.; Tytell, J.D.; Ingber, D.E. Mechanotransduction at a distance: Mechanically coupling the
extracellular matrix with the nucleus. Nat. Rev. Mol. Cell Biol. 2009, 10, 75–82. [CrossRef] [PubMed]
223. Crisp, M.; Liu, Q.; Roux, K.; Rattner, J.B.; Shanahan, C.; Burke, B.; Stahl, P.D.; Hodzic, D. Coupling of the
nucleus and cytoplasm: Role of the linc complex. J. Cell Biol. 2006, 172, 41–53. [CrossRef] [PubMed]
224. Fedorchak, G.R.; Kaminski, A.; Lammerding, J. Cellular mechanosensing: Getting to the nucleus of it all.
Prog. Biophys. Mol. Biol. 2014, 115, 76–92. [CrossRef] [PubMed]
225. Zhang, Q.; Skepper, J.N.; Yang, F.; Davies, J.D.; Hegyi, L.; Roberts, R.G.; Weissberg, P.L.; Ellis, J.A.;
Shanahan, C.M. Nesprins: A novel family of spectrin-repeat-containing proteins that localize to the nuclear
membrane in multiple tissues. J. Cell Sci. 2001, 114, 4485–4498. [PubMed]
226. Starr, D.A.; Fischer, J.A. Kash ’n karry: The KASH domain family of cargo-specific cytoskeletal adaptor
proteins. Bioessays 2005, 27, 1136–1146. [CrossRef] [PubMed]
227. Wilhelmsen, K.; Litjens, S.H.; Kuikman, I.; Tshimbalanga, N.; Janssen, H.; van den Bout, I.; Raymond, K.;
Sonnenberg, A. Nesprin-3, a novel outer nuclear membrane protein, associates with the cytoskeletal linker
protein plectin. J. Cell Biol. 2005, 171, 799–810. [CrossRef] [PubMed]
228. Hodzic, D.M.; Yeater, D.B.; Bengtsson, L.; Otto, H.; Stahl, P.D. SUN2 is a novel mammalian inner nuclear
membrane protein. J. Biol. Chem. 2004, 279, 25805–25812. [CrossRef] [PubMed]
229. Raff, J.W. The missing (L) UNC? Curr. Biol. 1999, 9, R708–R710. [CrossRef]
230. Haque, F.; Lloyd, D.J.; Smallwood, D.T.; Dent, C.L.; Shanahan, C.M.; Fry, A.M.; Trembath, R.C.; Shackleton, S.
SUN1 interacts with nuclear lamin a and cytoplasmic nesprins to provide a physical connection between the
nuclear lamina and the cytoskeleton. Mol. Cell. Biol. 2006, 26, 3738–3751. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 29 of 31
231. Nishioka, Y.; Imaizumi, H.; Imada, J.; Katahira, J.; Matsuura, N.; Hieda, M. SUN1 splice variants, SUN1_888,
SUN1_785, and predominant SUN1_916, variably function in directional cell migration. Nucleus 2016, 7,
572–584. [CrossRef] [PubMed]
232. Caputo, S.; Couprie, J.; Duband-Goulet, I.; Konde, E.; Lin, F.; Braud, S.; Gondry, M.; Gilquin, B.; Worman, H.J.;
Zinn-Justin, S. The carboxyl-terminal nucleoplasmic region of MAN1 exhibits a DNA binding winged helix
domain. J. Biol. Chem. 2006, 281, 18208–18215. [CrossRef] [PubMed]
233. Chang, W.; Worman, H.J.; Gundersen, G.G. Accessorizing and anchoring the linc complex for
multifunctionality. J. Cell Biol. 2015, 208, 11–22. [CrossRef] [PubMed]
234. Brosig, M.; Ferralli, J.; Gelman, L.; Chiquet, M.; Chiquet-Ehrismann, R. Interfering with the connection
between the nucleus and the cytoskeleton affects nuclear rotation, mechanotransduction and myogenesis.
Int. J. Biochem. Cell Biol. 2010, 42, 1717–1728. [CrossRef] [PubMed]
235. Puckelwartz, M.J.; Kessler, E.; Zhang, Y.; Hodzic, D.; Randles, K.N.; Morris, G.; Earley, J.U.; Hadhazy, M.;
Holaska, J.M.; Mewborn, S.K.; et al. Disruption of nesprin-1 produces an Emery Dreifuss muscular
dystrophy-like phenotype in mice. Hum. Mol. Genet. 2009, 18, 607–620. [CrossRef] [PubMed]
236. Dobrzynska, A.; Gonzalo, S.; Shanahan, C.; Askjaer, P. The nuclear lamina in health and disease. Nucleus
2016, 7, 233–248. [CrossRef] [PubMed]
237. Nikolova, V.; Leimena, C.; McMahon, A.C.; Tan, J.C.; Chandar, S.; Jogia, D.; Kesteven, S.H.; Michalicek, J.;
Otway, R.; Verheyen, F.; et al. Defects in nuclear structure and function promote dilated cardiomyopathy in
lamin A/C-deficient mice. J. Clin. Investig. 2004, 113, 357–369. [CrossRef] [PubMed]
238. Ho, C.Y.; Jaalouk, D.E.; Vartiainen, M.K.; Lammerding, J. Lamin A/C and emerin regulate MKL1-SRF activity
by modulating actin dynamics. Nature 2013, 497, 507–511. [CrossRef] [PubMed]
239. Arsenovic, P.T.; Ramachandran, I.; Bathula, K.; Zhu, R.; Narang, J.D.; Noll, N.A.; Lemmon, C.A.;
Gundersen, G.G.; Conway, D.E. Nesprin-2G, a component of the nuclear LINC complex, is subject to
myosin-dependent tension. Biophys. J. 2016, 110, 34–43. [CrossRef] [PubMed]
240. Rashmi, R.N.; Eckes, B.; Glockner, G.; Groth, M.; Neumann, S.; Gloy, J.; Sellin, L.; Walz, G.; Schneider, M.;
Karakesisoglou, I.; et al. The nuclear envelope protein nesprin-2 has roles in cell proliferation and
differentiation during wound healing. Nucleus 2012, 3, 172–186. [CrossRef] [PubMed]
241. Li, P.; Noegel, A.A. Inner nuclear envelope protein sun1 plays a prominent role in mammalian mRNA export.
Nucleic Acids Res. 2015, 43, 9874–9888. [CrossRef] [PubMed]
242. Alsarraj, J.; Faraji, F.; Geiger, T.R.; Mattaini, K.R.; Williams, M.; Wu, J.; Ha, N.H.; Merlino, T.; Walker, R.C.;
Bosley, A.D.; et al. BRD4 short isoform interacts with RRP1B, SIPA1 and components of the linc complex at
the inner face of the nuclear membrane. PLoS ONE 2013, 8. [CrossRef] [PubMed]
243. Tang, X.; Peng, R.; Ren, Y.; Apparsundaram, S.; Deguzman, J.; Bauer, C.M.; Hoffman, A.F.; Hamilton, S.;
Liang, Z.; Zeng, H.; et al. BET bromodomain proteins mediate downstream signaling events following
growth factor stimulation in human lung fibroblasts and are involved in bleomycin-induced pulmonary
fibrosis. Mol. Pharmacol. 2013, 83, 283–293. [CrossRef] [PubMed]
244. Ding, N.; Hah, N.; Yu, R.T.; Sherman, M.H.; Benner, C.; Leblanc, M.; He, M.; Liddle, C.; Downes, M.;
Evans, R.M. Brd4 is a novel therapeutic target for liver fibrosis. Proc. Natl. Acad. Sci. USA 2015, 112,
15713–15718. [CrossRef] [PubMed]
245. Sun, Y.; Huang, J.; Song, K. Bet protein inhibition mitigates acute myocardial infarction damage in rats via
the tlr4/traf6/nf-kappab pathway. Exp. Ther. Med. 2015, 10, 2319–2324. [PubMed]
246. Ding, X.; Xu, R.; Yu, J.; Xu, T.; Zhuang, Y.; Han, M. SUN1 is required for telomere attachment to nuclear
envelope and gametogenesis in mice. Dev. Cell 2007, 12, 863–872. [CrossRef] [PubMed]
247. Stewart-Hutchinson, P.J.; Hale, C.M.; Wirtz, D.; Hodzic, D. Structural requirements for the assembly of linc
complexes and their function in cellular mechanical stiffness. Exp. Cell Res. 2008, 314, 1892–1905. [CrossRef]
[PubMed]
248. Dahl, K.N.; Ribeiro, A.J.; Lammerding, J. Nuclear shape, mechanics, and mechanotransduction. Circ. Res.
2008, 102, 1307–1318. [CrossRef] [PubMed]
249. Caille, N.; Thoumine, O.; Tardy, Y.; Meister, J.J. Contribution of the nucleus to the mechanical properties of
endothelial cells. J. Biomech. 2002, 35, 177–187. [CrossRef]
250. Guilak, F.; Tedrow, J.R.; Burgkart, R. Viscoelastic properties of the cell nucleus. Biochem. Biophys. Res. Commun.
2000, 269, 781–786. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 30 of 31
251. Thomas, C.H.; Collier, J.H.; Sfeir, C.S.; Healy, K.E. Engineering gene expression and protein synthesis by
modulation of nuclear shape. Proc. Natl. Acad. Sci. USA 2002, 99, 1972–1977. [CrossRef] [PubMed]
252. Lovett, D.B.; Shekhar, N.; Nickerson, J.A.; Roux, K.J.; Lele, T.P. Modulation of nuclear shape by substrate
rigidity. Cell. Mol. Bioeng. 2013, 6, 230–238. [CrossRef] [PubMed]
253. Hubner, M.R.; Eckersley-Maslin, M.A.; Spector, D.L. Chromatin organization and transcriptional regulation.
Curr. Opin. Genet. Dev. 2013, 23, 89–95. [CrossRef] [PubMed]
254. Tajik, A.; Zhang, Y.; Wei, F.; Sun, J.; Jia, Q.; Zhou, W.; Singh, R.; Khanna, N.; Belmont, A.S.; Wang, N.
Transcription upregulation via force-induced direct stretching of chromatin. Nat. Mater. 2016, 15, 1287–1296.
[CrossRef] [PubMed]
255. Furusawa, T.; Rochman, M.; Taher, L.; Dimitriadis, E.K.; Nagashima, K.; Anderson, S.; Bustin, M. Chromatin
decompaction by the nucleosomal binding protein HMGN5 impairs nuclear sturdiness. Nat. Commun. 2015,
6. [CrossRef] [PubMed]
256. Rochman, M.; Postnikov, Y.; Correll, S.; Malicet, C.; Wincovitch, S.; Karpova, T.S.; McNally, J.G.; Wu, X.;
Bubunenko, N.A.; Grigoryev, S.; et al. The interaction of NSBP1/HMGN5 with nucleosomes in euchromatin
counteracts linker histone-mediated chromatin compaction and modulates transcription. Mol. Cell 2009, 35,
642–656. [CrossRef] [PubMed]
257. Fang, L.; Murphy, A.J.; Dart, A.M. A clinical perspective of anti-fibrotic therapies for cardiovascular disease.
Front. Pharmacol. 2017, 8. [CrossRef] [PubMed]
258. Teerlink, J.R.; Cotter, G.; Davison, B.A.; Felker, G.M.; Filippatos, G.; Greenberg, B.H.; Ponikowski, P.;
Unemori, E.; Voors, A.A.; Adams, K.F., Jr.; et al. Serelaxin, recombinant human relaxin-2, for treatment of
acute heart failure (relax-AHF): A randomised, placebo-controlled trial. Lancet 2013, 381, 29–39. [CrossRef]
259. Friedman, S.L.; Sheppard, D.; Duffield, J.S.; Violette, S. Therapy for fibrotic diseases: Nearing the starting
line. Sci. Transl. Med. 2013, 5. [CrossRef] [PubMed]
260. Hinz, B.; Gabbiani, G.; Chaponnier, C. The NH2-terminal peptide of α-smooth muscle actin inhibits force
generation by the myofibroblast in vitro and in vivo. J. Cell Biol. 2002, 157, 657–663. [CrossRef] [PubMed]
261. Yu-Wai-Man, C.; Spencer-Dene, B.; Lee, R.M.; Hutchings, K.; Lisabeth, E.M.; Treisman, R.; Bailly, M.;
Larsen, S.D.; Neubig, R.R.; Khaw, P.T. Local delivery of novel MRTF/SRF inhibitors prevents scar tissue
formation in a preclinical model of fibrosis. Sci. Rep. 2017, 7. [CrossRef] [PubMed]
262. Sisson, T.H.; Ajayi, I.O.; Subbotina, N.; Dodi, A.E.; Rodansky, E.S.; Chibucos, L.N.; Kim, K.K.;
Keshamouni, V.G.; White, E.S.; Zhou, Y.; et al. Inhibition of myocardin-related transcription factor/serum
response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis. Am. J. Pathol.
2015, 185, 969–986. [CrossRef] [PubMed]
263. Liu-Chittenden, Y.; Huang, B.; Shim, J.S.; Chen, Q.; Lee, S.J.; Anders, R.A.; Liu, J.O.; Pan, D. Genetic and
pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev.
2012, 26, 1300–1305. [CrossRef] [PubMed]
264. Yang, Y.; Del Re, D.P.; Nakano, N.; Sciarretta, S.; Zhai, P.; Park, J.; Sayed, D.; Shirakabe, A.; Matsushima, S.;
Park, Y.; et al. Mir-206 mediates yap-induced cardiac hypertrophy and survival. Circ. Res. 2015, 117, 891–904.
[CrossRef] [PubMed]
265. Kuwahara, K.; Kinoshita, H.; Kuwabara, Y.; Nakagawa, Y.; Usami, S.; Minami, T.; Yamada, Y.;
Fujiwara, M.; Nakao, K. Myocardin-related transcription factor a is a common mediator of mechanical
stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain
natriuretic peptide gene expression. Mol. Cell. Biol. 2010, 30, 4134–4148. [CrossRef] [PubMed]
266. Engler, A.J.; Sweeney, H.L.; Discher, D.E.; Schwarzbauer, J.E. Extracellular matrix elasticity directs stem cell
differentiation. J. Musculoskelet. Neuronal Interact. 2007, 7, 335. [PubMed]
267. Driesen, R.B.; Nagaraju, C.K.; Abi-Char, J.; Coenen, T.; Lijnen, P.J.; Fagard, R.H.; Sipido, K.R.; Petrov, V.V.
Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc. Res. 2014, 101, 411–422.
[CrossRef] [PubMed]
268. Kisseleva, T.; Cong, M.; Paik, Y.; Scholten, D.; Jiang, C.; Benner, C.; Iwaisako, K.; Moore-Morris, T.; Scott, B.;
Tsukamoto, H.; et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis.
Proc. Natl. Acad. Sci. USA 2012, 109, 9448–9453. [CrossRef] [PubMed]
269. Yang, X.; Chen, B.; Liu, T.; Chen, X. Reversal of myofibroblast differentiation: A review. Eur. J. Pharmacol.
2014, 734, 83–90. [CrossRef] [PubMed]
J. Clin. Med. 2017, 6, 53 31 of 31
270. Li, C.X.; Talele, N.P.; Boo, S.; Koehler, A.; Knee-Walden, E.; Balestrini, J.L.; Speight, P.; Kapus, A.; Hinz, B.
MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat. Mater. 2017, 16,
379–389. [CrossRef] [PubMed]
271. Enemchukwu, N.O.; Cruz-Acuna, R.; Bongiorno, T.; Johnson, C.T.; Garcia, J.R.; Sulchek, T.; Garcia, A.J.
Synthetic matrices reveal contributions of ECM biophysical and biochemical properties to epithelial
morphogenesis. J. Cell Biol. 2016, 212, 113–124. [CrossRef] [PubMed]
272. Wassenaar, J.W.; Gaetani, R.; Garcia, J.J.; Braden, R.L.; Luo, C.G.; Huang, D.; DeMaria, A.N.; Omens, J.H.;
Christman, K.L. Evidence for mechanisms underlying the functional benefits of a myocardial matrix hydrogel
for post-mi treatment. J. Am. Coll. Cardiol. 2016, 67, 1074–1086. [CrossRef] [PubMed]
273. Rodell, C.B.; Lee, M.E.; Wang, H.; Takebayashi, S.; Takayama, T.; Kawamura, T.; Arkles, J.S.; Dusaj, N.N.;
Dorsey, S.M.; Witschey, W.R.; et al. Injectable shear-thinning hydrogels for minimally invasive delivery
to infarcted myocardium to limit left ventricular remodeling. Circ. Cardiovasc. Interv. 2016, 9. [CrossRef]
[PubMed]
274. Perea-Gil, I.; Prat-Vidal, C.; Bayes-Genis, A. In vivo experience with natural scaffolds for myocardial
infarction: The times they are a-changin’. Stem Cell Res. Ther. 2015, 6. [CrossRef] [PubMed]
275. Wang, R.M.; Christman, K.L. Decellularized myocardial matrix hydrogels: In basic research and preclinical
studies. Adv. Drug Deliv. Rev. 2016, 96, 77–82. [CrossRef] [PubMed]
276. Yoshizumi, T.; Zhu, Y.; Jiang, H.; D’Amore, A.; Sakaguchi, H.; Tchao, J.; Tobita, K.; Wagner, W.R. Timing effect
of intramyocardial hydrogel injection for positively impacting left ventricular remodeling after myocardial
infarction. Biomaterials 2016, 83, 182–193. [CrossRef] [PubMed]
277. Sonnenberg, S.B.; Rane, A.A.; Liu, C.J.; Rao, N.; Agmon, G.; Suarez, S.; Wang, R.; Munoz, A.; Bajaj, V.;
Zhang, S.; et al. Delivery of an engineered hgf fragment in an extracellular matrix-derived hydrogel prevents
negative lv remodeling post-myocardial infarction. Biomaterials 2015, 45, 56–63. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
